https://trial.medpath.com/news/fda-clears-path-for-nebokitug-in-primary-sclerosing-cholangitis-treatment-following-successful-phase-2-meeting 2025-03-05T11:02:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-path-for-nebokitug-in-primary-sclerosing-cholangitis-treatment-following-successful-phase-2-meeting 2025-03-05T11:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-spark-biomedical-s-drug-free-neurostimulation-device-for-opioid-withdrawal 2025-03-05T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-spark-biomedical-s-drug-free-neurostimulation-device-for-opioid-withdrawal 2025-03-05T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-pharmaceuticals-reports-strong-growth-with-tavalisse-and-rezlidhia-in-2024-expands-global-reach 2025-03-05T08:02:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-pharmaceuticals-reports-strong-growth-with-tavalisse-and-rezlidhia-in-2024-expands-global-reach 2025-03-05T08:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-single-irb-mandate-set-to-streamline-clinical-trial-reviews-by-late-2024 2025-03-05T08:01:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-single-irb-mandate-set-to-streamline-clinical-trial-reviews-by-late-2024 2025-03-05T08:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/precise-hl-trial-launches-to-reduce-chemotherapy-in-hodgkin-lymphoma-using-ctdna-testing 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precise-hl-trial-launches-to-reduce-chemotherapy-in-hodgkin-lymphoma-using-ctdna-testing 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sernova-biotherapeutics-secures-5-million-in-financing-to-advance-type-1-diabetes-functional-cure 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sernova-biotherapeutics-secures-5-million-in-financing-to-advance-type-1-diabetes-functional-cure 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivosidenib-plus-cpx-351-shows-promise-in-idh1-mutated-aml-and-high-risk-mds-trial 2025-03-05T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivosidenib-plus-cpx-351-shows-promise-in-idh1-mutated-aml-and-high-risk-mds-trial 2025-03-05T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-signals-potential-shift-in-biosimilar-development-requirements-moving-away-from-phase-iii-trials 2025-03-05T07:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-signals-potential-shift-in-biosimilar-development-requirements-moving-away-from-phase-iii-trials 2025-03-05T07:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/garuda-therapeutics-names-avanish-vellanki-as-new-ceo-to-advance-off-the-shelf-stem-cell-platform 2025-03-05T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/garuda-therapeutics-names-avanish-vellanki-as-new-ceo-to-advance-off-the-shelf-stem-cell-platform 2025-03-05T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/tc-biopharm-to-acquire-ophthalmic-pharmaceutical-company-with-fda-approved-glaucoma-treatment 2025-03-05T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tc-biopharm-to-acquire-ophthalmic-pharmaceutical-company-with-fda-approved-glaucoma-treatment 2025-03-05T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/celon-pharma-s-pde10a-inhibitor-shows-significant-promise-in-phase-2-trial-for-parkinson-s-disease-dyskinesia 2025-03-05T04:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celon-pharma-s-pde10a-inhibitor-shows-significant-promise-in-phase-2-trial-for-parkinson-s-disease-dyskinesia 2025-03-05T04:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-epredia-s-e1000-dx-digital-pathology-solution-for-cancer-diagnostics 2025-03-05T04:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-epredia-s-e1000-dx-digital-pathology-solution-for-cancer-diagnostics 2025-03-05T04:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/matica-biotechnology-partners-with-childs-cure-to-develop-gene-therapy-for-rare-genetic-disorders 2025-03-05T04:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matica-biotechnology-partners-with-childs-cure-to-develop-gene-therapy-for-rare-genetic-disorders 2025-03-05T04:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/wehi-and-moderna-launch-pioneering-mrna-partnership-to-combat-autoimmune-diseases 2025-03-05T04:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wehi-and-moderna-launch-pioneering-mrna-partnership-to-combat-autoimmune-diseases 2025-03-05T04:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-artificial-photosynthesis-system-converts-waste-into-pharmaceutical-compounds 2025-03-05T04:32:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-artificial-photosynthesis-system-converts-waste-into-pharmaceutical-compounds 2025-03-05T04:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-and-sato-pharmaceutical-restructure-nailin-antifungal-marketing-partnership-in-japan 2025-03-05T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-and-sato-pharmaceutical-restructure-nailin-antifungal-marketing-partnership-in-japan 2025-03-05T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/microbiome-therapeutics-pipeline-expands-with-180-novel-therapies-in-development-across-140-companies 2025-03-05T04:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiome-therapeutics-pipeline-expands-with-180-novel-therapies-in-development-across-140-companies 2025-03-05T04:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/pharmamar-advances-lurbi-eadine-development-with-japanese-licensing-talks-and-european-submission-plans 2025-03-05T02:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmamar-advances-lurbi-eadine-development-with-japanese-licensing-talks-and-european-submission-plans 2025-03-05T02:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-cardiovascular-black-box-warning-from-testosterone-products-following-traverse-trial-results 2025-03-05T02:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-cardiovascular-black-box-warning-from-testosterone-products-following-traverse-trial-results 2025-03-05T02:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-s-can10-shows-promising-phase-1-results-for-hidradenitis-suppurativa-treatment 2025-03-05T01:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantargia-s-can10-shows-promising-phase-1-results-for-hidradenitis-suppurativa-treatment 2025-03-05T01:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/antihistamine-addition-to-atezolizumab-doubles-survival-rates-in-metastatic-urothelial-cancer 2025-03-05T01:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antihistamine-addition-to-atezolizumab-doubles-survival-rates-in-metastatic-urothelial-cancer 2025-03-05T01:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/oceanagold-advances-wharekirauponga-project-with-fast-track-application-and-high-grade-results 2025-03-05T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oceanagold-advances-wharekirauponga-project-with-fast-track-application-and-high-grade-results 2025-03-05T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-updates-testosterone-product-labels-following-traverse-trial-safety-data 2025-03-05T01:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-updates-testosterone-product-labels-following-traverse-trial-safety-data 2025-03-05T01:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/fatal-immune-checkpoint-inhibitor-overlap-syndrome-new-case-series-reveals-critical-management-insights 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fatal-immune-checkpoint-inhibitor-overlap-syndrome-new-case-series-reveals-critical-management-insights 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/minoryx-initiates-phase-2a-trial-of-leriglitazone-for-rett-syndrome 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minoryx-initiates-phase-2a-trial-of-leriglitazone-for-rett-syndrome 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-advances-dual-action-obesity-drug-survodutide-to-phase-3-trials 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-advances-dual-action-obesity-drug-survodutide-to-phase-3-trials 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-s-deramiocel-receives-fda-priority-review-for-duchenne-muscular-dystrophy-treatment 2025-03-04T22:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-s-deramiocel-receives-fda-priority-review-for-duchenne-muscular-dystrophy-treatment 2025-03-04T22:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-fecal-microbiota-pill-enters-clinical-trial-for-advanced-pancreatic-cancer-treatment 2025-03-04T22:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-fecal-microbiota-pill-enters-clinical-trial-for-advanced-pancreatic-cancer-treatment 2025-03-04T22:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-secures-250m-financing-for-us-launch-of-ros1-inhibitor-taletrectinib 2025-03-04T22:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvation-bio-secures-250m-financing-for-us-launch-of-ros1-inhibitor-taletrectinib 2025-03-04T22:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-reports-breakthrough-in-dmd-treatment-and-11-6-q4-revenue-growth 2025-03-04T22:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumberland-pharmaceuticals-reports-breakthrough-in-dmd-treatment-and-11-6-q4-revenue-growth 2025-03-04T22:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-emollient-plus-formulation-shows-superior-efficacy-in-atopic-dermatitis-treatment 2025-03-04T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-emollient-plus-formulation-shows-superior-efficacy-in-atopic-dermatitis-treatment 2025-03-04T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pipeline-drugs-show-promise-in-treating-severe-hypertriglyceridemia 2025-03-04T20:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pipeline-drugs-show-promise-in-treating-severe-hypertriglyceridemia 2025-03-04T20:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/senores-pharmaceuticals-acquires-14-andas-from-dr-reddy-s-in-421m-market-opportunity-deal 2025-03-04T20:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senores-pharmaceuticals-acquires-14-andas-from-dr-reddy-s-in-421m-market-opportunity-deal 2025-03-04T20:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-reports-universal-patient-response-in-corneal-stem-cell-therapy-trial 2025-03-04T20:00:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-reports-universal-patient-response-in-corneal-stem-cell-therapy-trial 2025-03-04T20:00:09+00:00 hourly 0.9 https://trial.medpath.com/news/first-ascent-biomedical-secures-florida-grant-to-expand-ai-driven-cancer-treatment-platform 2025-03-04T19:59:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-ascent-biomedical-secures-florida-grant-to-expand-ai-driven-cancer-treatment-platform 2025-03-04T19:59:28+00:00 hourly 0.9 https://trial.medpath.com/news/ema-s-chmp-issues-new-drug-recommendations-and-marketing-authorization-updates 2025-03-04T19:59:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-s-chmp-issues-new-drug-recommendations-and-marketing-authorization-updates 2025-03-04T19:59:11+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-revolutionizes-clinical-trial-workflows-with-launch-of-site-lab-navigator-e-requisition-platform 2025-03-04T19:58:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-revolutionizes-clinical-trial-workflows-with-launch-of-site-lab-navigator-e-requisition-platform 2025-03-04T19:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-reports-first-successful-tumor-infiltrating-lymphocyte-therapy-in-metastatic-melanoma-patient 2025-03-04T19:58:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-reports-first-successful-tumor-infiltrating-lymphocyte-therapy-in-metastatic-melanoma-patient 2025-03-04T19:58:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-nih-policy-shifts-spark-new-focus-on-clinical-trial-accessibility-and-technology-solutions 2025-03-04T19:58:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-nih-policy-shifts-spark-new-focus-on-clinical-trial-accessibility-and-technology-solutions 2025-03-04T19:58:13+00:00 hourly 0.9 https://trial.medpath.com/news/seagen-wins-42m-patent-verdict-against-daiichi-sankyo-over-enhertu-breast-cancer-drug 2025-03-04T19:56:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seagen-wins-42m-patent-verdict-against-daiichi-sankyo-over-enhertu-breast-cancer-drug 2025-03-04T19:56:34+00:00 hourly 0.9 https://trial.medpath.com/news/medable-secures-cnil-approval-for-digital-clinical-trial-solutions-in-european-union 2025-03-04T19:55:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medable-secures-cnil-approval-for-digital-clinical-trial-solutions-in-european-union 2025-03-04T19:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/auxora-shows-63-mortality-reduction-in-covid-19-patients-with-acute-kidney-injury 2025-03-04T19:55:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/auxora-shows-63-mortality-reduction-in-covid-19-patients-with-acute-kidney-injury 2025-03-04T19:55:08+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-report-promising-phase-3-results-for-chronic-rhinosinusitis-treatment 2025-03-04T19:54:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-companies-report-promising-phase-3-results-for-chronic-rhinosinusitis-treatment 2025-03-04T19:54:51+00:00 hourly 0.9 https://trial.medpath.com/news/masitinib-shows-promise-in-progressive-ms-treatment-leading-neurologist-highlights-novel-mechanism-of-action 2025-03-04T19:54:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/masitinib-shows-promise-in-progressive-ms-treatment-leading-neurologist-highlights-novel-mechanism-of-action 2025-03-04T19:54:30+00:00 hourly 0.9 https://trial.medpath.com/news/ga-depot-shows-promise-in-progressive-ms-with-3-year-stability-in-disability-scores 2025-03-04T19:54:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ga-depot-shows-promise-in-progressive-ms-with-3-year-stability-in-disability-scores 2025-03-04T19:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-discure-s-novel-bioelectronic-treatment-for-degenerative-disc-disease 2025-03-04T19:53:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-tracks-discure-s-novel-bioelectronic-treatment-for-degenerative-disc-disease 2025-03-04T19:53:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-pivotal-trial-of-novel-device-for-post-prostatectomy-incontinence-treatment 2025-03-04T19:53:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-pivotal-trial-of-novel-device-for-post-prostatectomy-incontinence-treatment 2025-03-04T19:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/rsv-treatment-landscape-expands-with-new-vaccines-and-clinical-trials-in-2024-2025 2025-03-04T19:53:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rsv-treatment-landscape-expands-with-new-vaccines-and-clinical-trials-in-2024-2025 2025-03-04T19:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/cingulate-s-once-daily-adhd-drug-ctx-1301-shows-promising-safety-profile-in-phase-3-trials 2025-03-04T19:52:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cingulate-s-once-daily-adhd-drug-ctx-1301-shows-promising-safety-profile-in-phase-3-trials 2025-03-04T19:52:43+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-bhv-7000-fails-primary-endpoint-in-pivotal-bipolar-disorder-trial 2025-03-04T19:52:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-bhv-7000-fails-primary-endpoint-in-pivotal-bipolar-disorder-trial 2025-03-04T19:52:22+00:00 hourly 0.9 https://trial.medpath.com/news/novel-dual-drug-combination-shows-promise-in-treating-resistant-acute-myeloid-leukemia 2025-03-04T19:52:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-dual-drug-combination-shows-promise-in-treating-resistant-acute-myeloid-leukemia 2025-03-04T19:52:03+00:00 hourly 0.9 https://trial.medpath.com/news/simbec-orion-and-avance-clinical-form-strategic-global-cro-partnership-to-enhance-clinical-trial-capabilities 2025-03-04T19:51:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simbec-orion-and-avance-clinical-form-strategic-global-cro-partnership-to-enhance-clinical-trial-capabilities 2025-03-04T19:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/lygenesis-s-phase-2a-liver-regeneration-trial-advances-to-higher-dosing-after-safety-milestone 2025-03-04T19:51:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lygenesis-s-phase-2a-liver-regeneration-trial-advances-to-higher-dosing-after-safety-milestone 2025-03-04T19:51:23+00:00 hourly 0.9 https://trial.medpath.com/news/verana-health-expands-site-explorer-tool-to-boost-diversity-in-clinical-trial-recruitment 2025-03-04T19:51:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verana-health-expands-site-explorer-tool-to-boost-diversity-in-clinical-trial-recruitment 2025-03-04T19:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/cadrenal-therapeutics-partners-with-abbott-to-advance-novel-anticoagulant-trial-for-lvad-patients 2025-03-04T19:50:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadrenal-therapeutics-partners-with-abbott-to-advance-novel-anticoagulant-trial-for-lvad-patients 2025-03-04T19:50:48+00:00 hourly 0.9 https://trial.medpath.com/news/icon-and-mural-health-partner-to-streamline-clinical-trial-participant-experience-with-digital-payment-platform 2025-03-04T19:50:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icon-and-mural-health-partner-to-streamline-clinical-trial-participant-experience-with-digital-payment-platform 2025-03-04T19:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/allurion-technologies-secures-new-patents-for-next-generation-obesity-treatment-device 2025-03-04T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allurion-technologies-secures-new-patents-for-next-generation-obesity-treatment-device 2025-03-04T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/ku-leuven-and-uz-leuven-launch-eur14-million-advanced-therapy-production-facility 2025-03-04T15:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ku-leuven-and-uz-leuven-launch-eur14-million-advanced-therapy-production-facility 2025-03-04T15:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacists-critical-role-in-improving-access-and-affordability-of-breast-cancer-therapies 2025-03-04T14:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacists-critical-role-in-improving-access-and-affordability-of-breast-cancer-therapies 2025-03-04T14:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/fairjourney-biologics-expands-global-footprint-with-acquisition-of-charles-river-s-superhuman-antibody-platform 2025-03-04T13:38:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fairjourney-biologics-expands-global-footprint-with-acquisition-of-charles-river-s-superhuman-antibody-platform 2025-03-04T13:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-terminates-rova-t-development-after-5-8b-stemcentrx-deal-becomes-major-r-d-setback 2025-03-04T13:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-terminates-rova-t-development-after-5-8b-stemcentrx-deal-becomes-major-r-d-setback 2025-03-04T13:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/enhertu-demonstrates-significant-overall-survival-benefit-in-her2-positive-breast-cancer-phase-iii-trial 2025-03-04T13:37:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhertu-demonstrates-significant-overall-survival-benefit-in-her2-positive-breast-cancer-phase-iii-trial 2025-03-04T13:37:45+00:00 hourly 0.9 https://trial.medpath.com/news/novel-autologous-cell-therapy-shows-92-success-rate-in-treating-limbal-stem-cell-deficiency 2025-03-04T13:37:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-autologous-cell-therapy-shows-92-success-rate-in-treating-limbal-stem-cell-deficiency 2025-03-04T13:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/phenomix-sciences-revolutionizes-obesity-treatment-with-precision-medicine-approach 2025-03-04T13:37:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phenomix-sciences-revolutionizes-obesity-treatment-with-precision-medicine-approach 2025-03-04T13:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-study-endometrial-immune-profiling-boosts-ivf-success-rates-by-40 2025-03-04T13:36:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-study-endometrial-immune-profiling-boosts-ivf-success-rates-by-40 2025-03-04T13:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/verigraft-secures-eur1-2m-grant-to-develop-revolutionary-3d-printed-vascular-grafts 2025-03-04T13:36:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verigraft-secures-eur1-2m-grant-to-develop-revolutionary-3d-printed-vascular-grafts 2025-03-04T13:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/eton-pharmaceuticals-launches-fda-approved-galzin-for-wilson-disease-maintenance-treatment 2025-03-04T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eton-pharmaceuticals-launches-fda-approved-galzin-for-wilson-disease-maintenance-treatment 2025-03-04T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/sofinnova-partners-secures-eur1-2-billion-to-fuel-next-wave-of-biotech-innovation 2025-03-04T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sofinnova-partners-secures-eur1-2-billion-to-fuel-next-wave-of-biotech-innovation 2025-03-04T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/dmc-approves-dose-escalation-in-spago-nanomedical-s-177lu-sn201-cancer-trial 2025-03-04T11:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dmc-approves-dose-escalation-in-spago-nanomedical-s-177lu-sn201-cancer-trial 2025-03-04T11:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/philips-initiates-class-i-recall-of-tack-endovascular-system-due-to-safety-concerns 2025-03-04T10:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philips-initiates-class-i-recall-of-tack-endovascular-system-due-to-safety-concerns 2025-03-04T10:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/milwaukee-va-emerges-as-top-center-for-veteran-cancer-clinical-trials-with-60-enrollment-rate 2025-03-04T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milwaukee-va-emerges-as-top-center-for-veteran-cancer-clinical-trials-with-60-enrollment-rate 2025-03-04T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/deepqure-s-novel-extravascular-rdn-device-shows-promise-in-global-hypertension-trials 2025-03-04T07:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepqure-s-novel-extravascular-rdn-device-shows-promise-in-global-hypertension-trials 2025-03-04T07:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funding-critical-for-addressing-gaps-in-pediatric-clinical-trials-study-reveals 2025-03-04T07:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-funding-critical-for-addressing-gaps-in-pediatric-clinical-trials-study-reveals 2025-03-04T07:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/cybrexa-s-novel-peptide-drug-conjugates-show-promising-tumor-selective-activity-in-preclinical-studies 2025-03-04T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cybrexa-s-novel-peptide-drug-conjugates-show-promising-tumor-selective-activity-in-preclinical-studies 2025-03-04T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/momentum-biotechnologies-acquires-omicscouts-to-expand-mass-spectrometry-based-drug-discovery-platform 2025-03-04T07:28:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/momentum-biotechnologies-acquires-omicscouts-to-expand-mass-spectrometry-based-drug-discovery-platform 2025-03-04T07:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/bioxcel-therapeutics-secures-14m-through-direct-stock-offering-to-institutional-investors 2025-03-04T05:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxcel-therapeutics-secures-14m-through-direct-stock-offering-to-institutional-investors 2025-03-04T05:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/aura-biosciences-to-present-new-phase-1-data-for-bel-sar-in-bladder-cancer-at-eau-2025 2025-03-04T05:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aura-biosciences-to-present-new-phase-1-data-for-bel-sar-in-bladder-cancer-at-eau-2025 2025-03-04T05:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-expands-hypertension-portfolio-with-540m-acquisition-of-israeli-tech-firm 2025-03-04T05:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-expands-hypertension-portfolio-with-540m-acquisition-of-israeli-tech-firm 2025-03-04T05:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-acquires-sonivie-for-540m-expanding-into-renal-denervation-market 2025-03-04T04:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-acquires-sonivie-for-540m-expanding-into-renal-denervation-market 2025-03-04T04:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ind-for-laekna-s-novel-usp1-inhibitor-lae120-for-advanced-solid-tumors 2025-03-04T04:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ind-for-laekna-s-novel-usp1-inhibitor-lae120-for-advanced-solid-tumors 2025-03-04T04:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/ubrigene-biosciences-advances-cell-therapy-development-with-dmf-submission-for-ipsc-reprogramming-kit 2025-03-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubrigene-biosciences-advances-cell-therapy-development-with-dmf-submission-for-ipsc-reprogramming-kit 2025-03-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adverum-launches-groundbreaking-phase-3-artemis-trial-for-one-time-gene-therapy-in-wet-amd 2025-03-04T01:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adverum-launches-groundbreaking-phase-3-artemis-trial-for-one-time-gene-therapy-in-wet-amd 2025-03-04T01:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-budget-cuts-under-trump-administration-threaten-drug-development-pipeline 2025-03-04T01:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-budget-cuts-under-trump-administration-threaten-drug-development-pipeline 2025-03-04T01:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/onward-medical-secures-2-5m-in-grants-to-explore-arc-im-system-for-parkinson-s-disease-symptoms 2025-03-04T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onward-medical-secures-2-5m-in-grants-to-explore-arc-im-system-for-parkinson-s-disease-symptoms 2025-03-04T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/centauri-therapeutics-advances-novel-immunotherapy-against-gram-negative-bacterial-infections-to-clinical-stage 2025-03-04T01:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centauri-therapeutics-advances-novel-immunotherapy-against-gram-negative-bacterial-infections-to-clinical-stage 2025-03-04T01:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-combination-overcomes-resistance-in-braf-mutated-melanoma-prevents-brain-metastasis 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-drug-combination-overcomes-resistance-in-braf-mutated-melanoma-prevents-brain-metastasis 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-leads-60-million-consortium-to-accelerate-uk-biobank-genome-sequencing-for-alzheimer-s-and-parkinson-s-drug-discovery 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-leads-60-million-consortium-to-accelerate-uk-biobank-genome-sequencing-for-alzheimer-s-and-parkinson-s-drug-discovery 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-il-12-delivery-system-shows-promise-for-advanced-ovarian-cancer-treatment 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-il-12-delivery-system-shows-promise-for-advanced-ovarian-cancer-treatment 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-diversifies-portfolio-with-fda-priority-review-for-upadacitinib-as-humira-faces-biosimilar-competition 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-diversifies-portfolio-with-fda-priority-review-for-upadacitinib-as-humira-faces-biosimilar-competition 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/acp-711-shows-promising-safety-profile-in-phase-1-multiple-ascending-dose-study-for-essential-tremor 2025-03-03T23:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acp-711-shows-promising-safety-profile-in-phase-1-multiple-ascending-dose-study-for-essential-tremor 2025-03-03T23:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/vaxcyte-nears-critical-phase-ii-readout-for-24-valent-pneumococcal-vaccine 2025-03-03T22:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxcyte-nears-critical-phase-ii-readout-for-24-valent-pneumococcal-vaccine 2025-03-03T22:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/malaria-drug-pyronaridine-shows-promise-as-novel-cancer-treatment 2025-03-03T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaria-drug-pyronaridine-shows-promise-as-novel-cancer-treatment 2025-03-03T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/ema-s-chmp-recommends-four-new-medicines-for-approval-reaffirms-leqembi-decision 2025-03-03T22:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-s-chmp-recommends-four-new-medicines-for-approval-reaffirms-leqembi-decision 2025-03-03T22:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ani-pharmaceuticals-cortrophin-gel-prefilled-syringe-for-multiple-autoimmune-conditions 2025-03-03T22:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ani-pharmaceuticals-cortrophin-gel-prefilled-syringe-for-multiple-autoimmune-conditions 2025-03-03T22:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitors-pipeline-expands-with-55-drug-candidates-as-major-pharma-companies-drive-innovation 2025-03-03T22:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitors-pipeline-expands-with-55-drug-candidates-as-major-pharma-companies-drive-innovation 2025-03-03T22:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/tenaya-therapeutics-launches-public-offering-to-advance-cardiac-gene-therapy-pipeline 2025-03-03T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenaya-therapeutics-launches-public-offering-to-advance-cardiac-gene-therapy-pipeline 2025-03-03T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-s-essential-tremor-trial-halted-after-disappointing-interim-analysis 2025-03-03T21:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-s-essential-tremor-trial-halted-after-disappointing-interim-analysis 2025-03-03T21:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/deucrictibant-shows-promising-long-term-safety-and-efficacy-in-hereditary-angioedema-treatment 2025-03-03T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deucrictibant-shows-promising-long-term-safety-and-efficacy-in-hereditary-angioedema-treatment 2025-03-03T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/berberine-based-drug-htd1801-shows-promising-results-in-type-2-diabetes-phase-2-trial 2025-03-03T19:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/berberine-based-drug-htd1801-shows-promising-results-in-type-2-diabetes-phase-2-trial 2025-03-03T19:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/selpercatinib-shows-sustained-long-term-efficacy-in-ret-fusion-positive-nsclc-patients 2025-03-03T19:35:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selpercatinib-shows-sustained-long-term-efficacy-in-ret-fusion-positive-nsclc-patients 2025-03-03T19:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-and-takeda-s-rusfertide-shows-positive-phase-3-results-in-polycythemia-vera 2025-03-03T19:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-and-takeda-s-rusfertide-shows-positive-phase-3-results-in-polycythemia-vera 2025-03-03T19:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-faces-setback-as-essential-tremor-drug-trial-falls-short-of-expectations 2025-03-03T19:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-faces-setback-as-essential-tremor-drug-trial-falls-short-of-expectations 2025-03-03T19:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/uc-santa-cruz-clinical-lab-receives-clia-certification-for-revolutionary-pediatric-cancer-rna-testing 2025-03-03T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-santa-cruz-clinical-lab-receives-clia-certification-for-revolutionary-pediatric-cancer-rna-testing 2025-03-03T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/eco-animal-health-submits-first-eu-vaccine-application-for-poultry-mycoplasma-treatment 2025-03-03T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eco-animal-health-submits-first-eu-vaccine-application-for-poultry-mycoplasma-treatment 2025-03-03T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-of-220-drugs-advancing-for-gastric-cancer-treatment-led-by-major-pharmaceutical-companies 2025-03-03T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-pipeline-of-220-drugs-advancing-for-gastric-cancer-treatment-led-by-major-pharmaceutical-companies 2025-03-03T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-for-ewing-sarcoma-treatment-25-companies-advancing-novel-therapies 2025-03-03T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-pipeline-for-ewing-sarcoma-treatment-25-companies-advancing-novel-therapies 2025-03-03T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/aion-healthspan-launches-first-human-trial-of-rejuvxl-cell-therapy-for-chronic-kidney-disease 2025-03-03T19:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aion-healthspan-launches-first-human-trial-of-rejuvxl-cell-therapy-for-chronic-kidney-disease 2025-03-03T19:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-launches-otulfi-new-stelara-biosimilar-in-us-and-european-markets 2025-03-03T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-launches-otulfi-new-stelara-biosimilar-in-us-and-european-markets 2025-03-03T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-genentech-s-tnkase-for-acute-ischemic-stroke-with-simplified-administration 2025-03-03T19:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-genentech-s-tnkase-for-acute-ischemic-stroke-with-simplified-administration 2025-03-03T19:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/myosin-therapeutics-secures-3m-in-second-seed-funding-to-advance-brain-cancer-and-addiction-therapies 2025-03-03T19:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myosin-therapeutics-secures-3m-in-second-seed-funding-to-advance-brain-cancer-and-addiction-therapies 2025-03-03T19:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-diagnamed-s-molecular-hydrogen-therapy-for-als 2025-03-03T18:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-diagnamed-s-molecular-hydrogen-therapy-for-als 2025-03-03T18:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-breakthrough-therapy-status-emerges-as-game-changer-for-oncology-drug-development 2025-03-03T17:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-breakthrough-therapy-status-emerges-as-game-changer-for-oncology-drug-development 2025-03-03T17:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-biopharma-secures-strong-financial-position-with-266-5m-cash-reserve-following-successful-ipo 2025-03-03T17:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrivent-biopharma-secures-strong-financial-position-with-266-5m-cash-reserve-following-successful-ipo 2025-03-03T17:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/essential-tremor-drug-development-faces-setbacks-as-multiple-clinical-trials-report-disappointing-results 2025-03-03T17:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essential-tremor-drug-development-faces-setbacks-as-multiple-clinical-trials-report-disappointing-results 2025-03-03T17:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/california-s-state-branded-insulin-program-faces-significant-delays-no-clear-launch-timeline 2025-03-03T17:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-s-state-branded-insulin-program-faces-significant-delays-no-clear-launch-timeline 2025-03-03T17:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/genevant-and-arbutus-launch-global-patent-battle-against-moderna-over-lnp-technology-in-covid-19-vaccine 2025-03-03T17:02:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genevant-and-arbutus-launch-global-patent-battle-against-moderna-over-lnp-technology-in-covid-19-vaccine 2025-03-03T17:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/gensaic-and-novo-nordisk-partner-to-develop-novel-precision-therapeutics-platform 2025-03-03T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensaic-and-novo-nordisk-partner-to-develop-novel-precision-therapeutics-platform 2025-03-03T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/elucid-strengthens-leadership-team-to-launch-ai-powered-atherosclerosis-analysis-software-plaqueiq 2025-03-03T17:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elucid-strengthens-leadership-team-to-launch-ai-powered-atherosclerosis-analysis-software-plaqueiq 2025-03-03T17:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/inka-health-pioneers-ai-driven-synthetic-patient-models-for-advancing-oncology-research 2025-03-03T16:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inka-health-pioneers-ai-driven-synthetic-patient-models-for-advancing-oncology-research 2025-03-03T16:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/batteryless-neurostimulator-shows-promising-6-month-results-for-overactive-bladder-treatment 2025-03-03T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/batteryless-neurostimulator-shows-promising-6-month-results-for-overactive-bladder-treatment 2025-03-03T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/trilaciclib-shows-strong-myeloprotection-but-mixed-efficacy-results-in-metastatic-colorectal-cancer-trial 2025-03-03T16:39:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trilaciclib-shows-strong-myeloprotection-but-mixed-efficacy-results-in-metastatic-colorectal-cancer-trial 2025-03-03T16:39:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-concludes-inspection-of-bioxcel-s-tranquility-ii-phase-3-trial-site-with-vai-status 2025-03-03T16:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-concludes-inspection-of-bioxcel-s-tranquility-ii-phase-3-trial-site-with-vai-status 2025-03-03T16:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/oh2-oncolytic-virus-plus-hx008-shows-promise-in-advanced-sarcoma-treatment 2025-03-03T16:38:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oh2-oncolytic-virus-plus-hx008-shows-promise-in-advanced-sarcoma-treatment 2025-03-03T16:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-phase-1-trial-of-abs-0871-for-charcot-marie-tooth-disease-2c-treatment 2025-03-03T16:38:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-1-trial-of-abs-0871-for-charcot-marie-tooth-disease-2c-treatment 2025-03-03T16:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/wren-laboratories-launches-advanced-netest-2-0-for-enhanced-neuroendocrine-tumor-diagnostics 2025-03-03T16:38:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wren-laboratories-launches-advanced-netest-2-0-for-enhanced-neuroendocrine-tumor-diagnostics 2025-03-03T16:38:11+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-pioneers-novel-opioids-with-built-in-overdose-prevention-technology 2025-03-03T16:37:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-pioneers-novel-opioids-with-built-in-overdose-prevention-technology 2025-03-03T16:37:52+00:00 hourly 0.9 https://trial.medpath.com/news/rome-therapeutics-landmark-study-reveals-novel-line-1-activity-patterns-across-cancer-types 2025-03-03T16:37:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rome-therapeutics-landmark-study-reveals-novel-line-1-activity-patterns-across-cancer-types 2025-03-03T16:37:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-latigo-s-novel-non-opioid-pain-treatment-ltg-001 2025-03-03T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-latigo-s-novel-non-opioid-pain-treatment-ltg-001 2025-03-03T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/mental-health-concerns-rise-as-weight-loss-drug-users-report-increased-anxiety-and-panic-attacks 2025-03-03T16:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mental-health-concerns-rise-as-weight-loss-drug-users-report-increased-anxiety-and-panic-attacks 2025-03-03T16:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/revive-therapeutics-to-acquire-diagnamed-s-molecular-hydrogen-program-for-als-and-brain-disorders 2025-03-03T16:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revive-therapeutics-to-acquire-diagnamed-s-molecular-hydrogen-program-for-als-and-brain-disorders 2025-03-03T16:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-prepares-for-major-launch-of-long-acting-hiv-prevention-drug 2025-03-03T16:36:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-prepares-for-major-launch-of-long-acting-hiv-prevention-drug 2025-03-03T16:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-secures-250m-financing-package-to-launch-novel-lung-cancer-drug-taletrectinib 2025-03-03T16:35:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvation-bio-secures-250m-financing-package-to-launch-novel-lung-cancer-drug-taletrectinib 2025-03-03T16:35:53+00:00 hourly 0.9 https://trial.medpath.com/news/callio-therapeutics-secures-187m-series-a-to-develop-novel-multi-payload-cancer-adcs 2025-03-03T16:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/callio-therapeutics-secures-187m-series-a-to-develop-novel-multi-payload-cancer-adcs 2025-03-03T16:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-s-non-opioid-pain-drug-pilavapadin-misses-primary-endpoint-in-phase-iib-diabetic-neuropathy-trial 2025-03-03T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexicon-s-non-opioid-pain-drug-pilavapadin-misses-primary-endpoint-in-phase-iib-diabetic-neuropathy-trial 2025-03-03T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/rusfertide-shows-promising-results-in-phase-3-trial-for-polycythemia-vera-treatment 2025-03-03T16:33:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rusfertide-shows-promising-results-in-phase-3-trial-for-polycythemia-vera-treatment 2025-03-03T16:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-first-chikungunya-vaccine-from-bavarian-nordic 2025-03-03T16:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-first-chikungunya-vaccine-from-bavarian-nordic 2025-03-03T16:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/biond-biologics-reclaims-bnd-22-rights-from-sanofi-following-promising-phase-1-results-in-cancer-treatment 2025-03-03T16:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biond-biologics-reclaims-bnd-22-rights-from-sanofi-following-promising-phase-1-results-in-cancer-treatment 2025-03-03T16:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-and-ipsen-advance-second-novel-t-cell-activator-drug-candidate-for-cancer-immunotherapy 2025-03-03T16:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-and-ipsen-advance-second-novel-t-cell-activator-drug-candidate-for-cancer-immunotherapy 2025-03-03T16:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trials-for-myelodysplastic-syndrome-show-significant-industry-investment-in-2025 2025-03-03T16:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-clinical-trials-for-myelodysplastic-syndrome-show-significant-industry-investment-in-2025 2025-03-03T16:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/ema-launches-interactive-clinical-trials-map-to-boost-patient-engagement-in-eu-studies 2025-03-03T16:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-launches-interactive-clinical-trials-map-to-boost-patient-engagement-in-eu-studies 2025-03-03T16:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/nexalin-secures-uspto-patent-allowance-for-novel-non-invasive-addiction-treatment-technology 2025-03-03T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexalin-secures-uspto-patent-allowance-for-novel-non-invasive-addiction-treatment-technology 2025-03-03T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-secures-7-6-million-private-placement-to-advance-novel-adc-platform 2025-03-03T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-therapeutics-secures-7-6-million-private-placement-to-advance-novel-adc-platform 2025-03-03T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/naxitamab-shows-promising-results-in-phase-2-trial-for-high-risk-neuroblastoma 2025-03-03T14:01:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/naxitamab-shows-promising-results-in-phase-2-trial-for-high-risk-neuroblastoma 2025-03-03T14:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-completes-enrollment-in-phase-2-trial-of-canvuparatide-for-hypoparathyroidism 2025-03-03T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbx-biosciences-completes-enrollment-in-phase-2-trial-of-canvuparatide-for-hypoparathyroidism 2025-03-03T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/esperion-expands-global-reach-new-partnerships-with-csl-seqirus-and-hls-therapeutics-for-nexletol-and-nexlizet 2025-03-03T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esperion-expands-global-reach-new-partnerships-with-csl-seqirus-and-hls-therapeutics-for-nexletol-and-nexlizet 2025-03-03T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-achieves-multiple-milestones-in-q1-2024-advances-anktiva-development-with-rmat-designation 2025-03-03T13:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-achieves-multiple-milestones-in-q1-2024-advances-anktiva-development-with-rmat-designation 2025-03-03T13:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/metis-pharmaceuticals-strengthens-leadership-team-with-appointment-of-mark-herbert-as-chief-business-officer 2025-03-03T13:34:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-pharmaceuticals-strengthens-leadership-team-with-appointment-of-mark-herbert-as-chief-business-officer 2025-03-03T13:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/vegen-labs-receives-3-765-crore-birac-grant-to-advance-novel-kras-inhibitor-for-lung-cancer-treatment 2025-03-03T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vegen-labs-receives-3-765-crore-birac-grant-to-advance-novel-kras-inhibitor-for-lung-cancer-treatment 2025-03-03T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-and-attmos-partner-to-pioneer-ai-driven-drug-discovery-for-undruggable-cancer-targets 2025-03-03T13:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-and-attmos-partner-to-pioneer-ai-driven-drug-discovery-for-undruggable-cancer-targets 2025-03-03T13:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-bexmarilimab-for-myelodysplastic-syndrome-treatment 2025-03-03T13:32:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-bexmarilimab-for-myelodysplastic-syndrome-treatment 2025-03-03T13:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/pulnovo-medical-raises-100m-to-advance-pulmonary-hypertension-treatment-development 2025-03-03T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulnovo-medical-raises-100m-to-advance-pulmonary-hypertension-treatment-development 2025-03-03T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-enters-obesity-market-with-350m-gubra-deal-for-novel-amylin-analog 2025-03-03T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-enters-obesity-market-with-350m-gubra-deal-for-novel-amylin-analog 2025-03-03T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-novel-treatment-shows-promising-results-in-phase-iii-trials-for-chronic-rhinosinusitis-with-nasal-polyps 2025-03-03T13:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-novel-treatment-shows-promising-results-in-phase-iii-trials-for-chronic-rhinosinusitis-with-nasal-polyps 2025-03-03T13:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-gene-therapy-for-maple-syrup-urine-disease-shows-promise-in-animal-models 2025-03-03T10:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-gene-therapy-for-maple-syrup-urine-disease-shows-promise-in-animal-models 2025-03-03T10:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-xolair-shows-promising-results-in-phase-iii-study-for-chronic-spontaneous-urticaria 2025-03-03T10:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-xolair-shows-promising-results-in-phase-iii-study-for-chronic-spontaneous-urticaria 2025-03-03T10:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-declares-end-to-ozempic-shortage-while-australian-supply-remains-limited-until-2025 2025-03-03T10:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-declares-end-to-ozempic-shortage-while-australian-supply-remains-limited-until-2025 2025-03-03T10:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-launches-chocola-bb-nightwell-novel-sleep-time-fatigue-recovery-drink 2025-03-03T10:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-launches-chocola-bb-nightwell-novel-sleep-time-fatigue-recovery-drink 2025-03-03T10:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-and-osaka-metropolitan-university-form-strategic-alliance-to-combat-infectious-diseases 2025-03-03T10:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-and-osaka-metropolitan-university-form-strategic-alliance-to-combat-infectious-diseases 2025-03-03T10:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/peptide-formulation-delivery-summit-to-address-key-challenges-in-therapeutic-development 2025-03-03T09:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptide-formulation-delivery-summit-to-address-key-challenges-in-therapeutic-development 2025-03-03T09:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-durvalumab-tremelimumab-combination-approved-for-liver-cancer-treatment-in-india 2025-03-03T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-durvalumab-tremelimumab-combination-approved-for-liver-cancer-treatment-in-india 2025-03-03T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-expands-injectable-portfolio-with-acetylcysteine-acquisition-and-us-launch 2025-03-03T07:32:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-expands-injectable-portfolio-with-acetylcysteine-acquisition-and-us-launch 2025-03-03T07:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/ncx-470-shows-superior-iop-control-over-latanoprost-in-mont-blanc-trial-analysis 2025-03-03T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ncx-470-shows-superior-iop-control-over-latanoprost-in-mont-blanc-trial-analysis 2025-03-03T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/blackstone-acquires-60-stake-in-cmic-to-accelerate-drug-development-in-japan 2025-03-03T07:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blackstone-acquires-60-stake-in-cmic-to-accelerate-drug-development-in-japan 2025-03-03T07:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-advances-revolutionary-psilocybin-treatment-comp360-into-phase-3-trials-for-treatment-resistant-depression 2025-03-03T04:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-pathways-advances-revolutionary-psilocybin-treatment-comp360-into-phase-3-trials-for-treatment-resistant-depression 2025-03-03T04:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-partners-with-basgenbio-for-ai-powered-clinical-trial-simulation-in-breast-cancer-research 2025-03-03T04:32:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-partners-with-basgenbio-for-ai-powered-clinical-trial-simulation-in-breast-cancer-research 2025-03-03T04:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/novel-fenugreek-based-nanoparticles-show-promise-in-enhancing-diabetes-drug-delivery 2025-03-03T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-fenugreek-based-nanoparticles-show-promise-in-enhancing-diabetes-drug-delivery 2025-03-03T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/pulnovo-medical-secures-100m-series-c-funding-to-advance-pulmonary-hypertension-treatment 2025-03-03T04:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulnovo-medical-secures-100m-series-c-funding-to-advance-pulmonary-hypertension-treatment 2025-03-03T04:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/clarity-pharmaceuticals-reports-widening-losses-amid-expanded-r-d-investment-in-radiopharmaceuticals 2025-03-03T04:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clarity-pharmaceuticals-reports-widening-losses-amid-expanded-r-d-investment-in-radiopharmaceuticals 2025-03-03T04:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/xolair-study-shows-promise-majority-of-children-successfully-consume-allergens-after-treatment-discontinuation 2025-03-03T02:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xolair-study-shows-promise-majority-of-children-successfully-consume-allergens-after-treatment-discontinuation 2025-03-03T02:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/avecho-and-sandoz-partner-in-landmark-19m-deal-to-develop-otc-cbd-insomnia-treatment 2025-03-03T01:33:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avecho-and-sandoz-partner-in-landmark-19m-deal-to-develop-otc-cbd-insomnia-treatment 2025-03-03T01:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-greenlights-amplia-s-protocol-for-narmafotinib-folfirinox-combination-trial-in-advanced-pancreatic-cancer 2025-03-03T01:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-greenlights-amplia-s-protocol-for-narmafotinib-folfirinox-combination-trial-in-advanced-pancreatic-cancer 2025-03-03T01:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/xolair-shows-superior-efficacy-over-oral-immunotherapy-in-landmark-food-allergy-trial 2025-03-03T01:32:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xolair-shows-superior-efficacy-over-oral-immunotherapy-in-landmark-food-allergy-trial 2025-03-03T01:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/early-leqembi-patient-s-journey-highlights-promise-and-limitations-of-new-alzheimer-s-treatment 2025-03-03T01:32:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-leqembi-patient-s-journey-highlights-promise-and-limitations-of-new-alzheimer-s-treatment 2025-03-03T01:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-s-car-t-cell-therapy-shows-promise-in-early-patient-testing 2025-03-03T01:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-s-car-t-cell-therapy-shows-promise-in-early-patient-testing 2025-03-03T01:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/tezepelumab-shows-79-reduction-in-severe-asthma-exacerbations-in-real-world-study 2025-03-03T01:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tezepelumab-shows-79-reduction-in-severe-asthma-exacerbations-in-real-world-study 2025-03-03T01:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/anaphylm-shows-consistent-efficacy-despite-oral-allergy-syndrome-complications 2025-03-03T01:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anaphylm-shows-consistent-efficacy-despite-oral-allergy-syndrome-complications 2025-03-03T01:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/rising-sirturo-resistance-threatens-tb-treatment-progress-experts-call-for-new-therapies 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rising-sirturo-resistance-threatens-tb-treatment-progress-experts-call-for-new-therapies 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-highlights-benefits-of-maintaining-high-factor-viii-levels-in-hemophilia-a-patients 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-highlights-benefits-of-maintaining-high-factor-viii-levels-in-hemophilia-a-patients 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-m-a-activity-reaches-79-4-billion-in-2024-despite-50-drop-from-previous-year 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-m-a-activity-reaches-79-4-billion-in-2024-despite-50-drop-from-previous-year 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-field-forces-embrace-customer-centric-approach-in-digital-transformation-era 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-field-forces-embrace-customer-centric-approach-in-digital-transformation-era 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-version-of-astrazeneca-s-symbicort-for-asthma-and-copd 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-generic-version-of-astrazeneca-s-symbicort-for-asthma-and-copd 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/evolving-market-access-challenges-reshape-pharmaceutical-industry-strategy 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolving-market-access-challenges-reshape-pharmaceutical-industry-strategy 2025-03-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-data-shows-no-survival-advantage-for-salvage-transplant-vs-lenalidomide-in-relapsed-multiple-myeloma 2025-03-02T22:31:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-data-shows-no-survival-advantage-for-salvage-transplant-vs-lenalidomide-in-relapsed-multiple-myeloma 2025-03-02T22:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-advances-ai-driven-cancer-treatment-through-strategic-partnerships 2025-03-02T22:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-advances-ai-driven-cancer-treatment-through-strategic-partnerships 2025-03-02T22:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-pharmaceuticals-initiates-major-recall-of-adhd-medication-in-us-market 2025-03-02T19:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-pharmaceuticals-initiates-major-recall-of-adhd-medication-in-us-market 2025-03-02T19:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/novel-anti-ige-antibody-lp-003-shows-superior-efficacy-over-omalizumab-in-chronic-spontaneous-urticaria-trial 2025-03-02T19:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-anti-ige-antibody-lp-003-shows-superior-efficacy-over-omalizumab-in-chronic-spontaneous-urticaria-trial 2025-03-02T19:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/herpes-zoster-vaccine-shows-strong-protection-for-stem-cell-transplant-recipients-meta-analysis-reveals 2025-03-02T19:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/herpes-zoster-vaccine-shows-strong-protection-for-stem-cell-transplant-recipients-meta-analysis-reveals 2025-03-02T19:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-shows-consistent-efficacy-in-eoe-treatment-independent-of-food-elimination-diets 2025-03-02T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-shows-consistent-efficacy-in-eoe-treatment-independent-of-food-elimination-diets 2025-03-02T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/high-blood-eosinophils-and-feno-levels-predict-better-dupilumab-response-in-moderate-to-severe-asthma 2025-03-02T16:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-blood-eosinophils-and-feno-levels-predict-better-dupilumab-response-in-moderate-to-severe-asthma 2025-03-02T16:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-nivolumab-ipilimumab-combination-for-first-line-treatment-of-dmmr-msi-h-colorectal-cancer 2025-03-02T14:01:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-nivolumab-ipilimumab-combination-for-first-line-treatment-of-dmmr-msi-h-colorectal-cancer 2025-03-02T14:01:47+00:00 hourly 0.9 https://trial.medpath.com/news/alto-s-alto-300-shows-promise-in-phase-2b-trial-for-treatment-resistant-depression 2025-03-02T13:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alto-s-alto-300-shows-promise-in-phase-2b-trial-for-treatment-resistant-depression 2025-03-02T13:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-novabay-s-novel-dual-action-eye-infection-treatment-nvc-422-for-clinical-trials 2025-03-02T07:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-novabay-s-novel-dual-action-eye-infection-treatment-nvc-422-for-clinical-trials 2025-03-02T07:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-toripalimab-review-for-nasopharyngeal-carcinoma-due-to-pending-manufacturing-site-inspection 2025-03-02T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-delays-toripalimab-review-for-nasopharyngeal-carcinoma-due-to-pending-manufacturing-site-inspection 2025-03-02T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/actigraph-and-biofourmis-partner-to-advance-digital-data-collection-in-clinical-trials 2025-03-02T07:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actigraph-and-biofourmis-partner-to-advance-digital-data-collection-in-clinical-trials 2025-03-02T07:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-diversity-crisis-dr-karen-winkfield-outlines-solutions-for-inclusive-patient-participation 2025-03-02T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-diversity-crisis-dr-karen-winkfield-outlines-solutions-for-inclusive-patient-participation 2025-03-02T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-expands-molecular-biology-portfolio-with-sabiosciences-acquisition 2025-03-02T01:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-expands-molecular-biology-portfolio-with-sabiosciences-acquisition 2025-03-02T01:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/zervimesine-shows-promise-in-dry-amd-treatment-with-positive-phase-2-data 2025-03-02T01:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zervimesine-shows-promise-in-dry-amd-treatment-with-positive-phase-2-data 2025-03-02T01:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-merck-s-personalized-cancer-vaccine-shows-strong-promise-in-advanced-melanoma-trial 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-merck-s-personalized-cancer-vaccine-shows-strong-promise-in-advanced-melanoma-trial 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-reverses-decision-approves-braftovi-erbitux-combination-for-braf-mutated-colorectal-cancer 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-reverses-decision-approves-braftovi-erbitux-combination-for-braf-mutated-colorectal-cancer 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/four-new-humira-biosimilars-launch-in-us-market-with-steep-discounts-up-to-85 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-new-humira-biosimilars-launch-in-us-market-with-steep-discounts-up-to-85 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/four-new-humira-biosimilars-launch-in-us-market-with-steep-discounts-up-to-85 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-new-humira-biosimilars-launch-in-us-market-with-steep-discounts-up-to-85 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-and-galapagos-form-406-million-alliance-to-develop-novel-cystic-fibrosis-therapies 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-and-galapagos-form-406-million-alliance-to-develop-novel-cystic-fibrosis-therapies 2025-03-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-advances-novel-obesity-drug-development-with-global-launch-plans 2025-03-01T22:32:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-advances-novel-obesity-drug-development-with-global-launch-plans 2025-03-01T22:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-uncover-new-druggable-site-on-eif4e-protein-opening-path-for-novel-cancer-therapeutics 2025-03-01T22:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-uncover-new-druggable-site-on-eif4e-protein-opening-path-for-novel-cancer-therapeutics 2025-03-01T22:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/apogee-therapeutics-to-present-phase-1-apg990-trial-results-for-inflammatory-disease-treatment 2025-03-01T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apogee-therapeutics-to-present-phase-1-apg990-trial-results-for-inflammatory-disease-treatment 2025-03-01T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-acquires-amplyx-pharmaceuticals-to-advance-novel-antifungal-development 2025-03-01T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-acquires-amplyx-pharmaceuticals-to-advance-novel-antifungal-development 2025-03-01T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-auto4-shows-promise-in-treating-peripheral-t-cell-lymphoma 2025-03-01T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-auto4-shows-promise-in-treating-peripheral-t-cell-lymphoma 2025-03-01T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/caliway-biopharmaceuticals-secures-record-breaking-206m-ipo-advances-novel-fat-reduction-drug-development 2025-03-01T19:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caliway-biopharmaceuticals-secures-record-breaking-206m-ipo-advances-novel-fat-reduction-drug-development 2025-03-01T19:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/battery-free-sacral-neuromodulation-device-shows-84-success-rate-in-treating-urinary-incontinence 2025-03-01T19:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/battery-free-sacral-neuromodulation-device-shows-84-success-rate-in-treating-urinary-incontinence 2025-03-01T19:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-light-therapy-trial-launches-to-combat-progressive-ms-related-fatigue 2025-03-01T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-light-therapy-trial-launches-to-combat-progressive-ms-related-fatigue 2025-03-01T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-radiotherapy-approach-helps-rectal-cancer-patients-avoid-permanent-stoma-surgery 2025-03-01T19:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-radiotherapy-approach-helps-rectal-cancer-patients-avoid-permanent-stoma-surgery 2025-03-01T19:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/smithrx-expands-autoimmune-program-with-stelara-biosimilars-projects-14-5m-annual-savings 2025-03-01T17:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smithrx-expands-autoimmune-program-with-stelara-biosimilars-projects-14-5m-annual-savings 2025-03-01T17:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-giants-invest-34-billion-in-manufacturing-scale-up-for-weight-loss-drugs 2025-03-01T16:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-giants-invest-34-billion-in-manufacturing-scale-up-for-weight-loss-drugs 2025-03-01T16:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/diagnos-inc-pursues-fda-authorization-for-ai-powered-retinal-disease-detection-system 2025-03-01T16:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diagnos-inc-pursues-fda-authorization-for-ai-powered-retinal-disease-detection-system 2025-03-01T16:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-new-guidance-on-electronic-systems-in-clinical-trials-enhanced-data-integrity-and-digital-health-integration 2025-03-01T16:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-new-guidance-on-electronic-systems-in-clinical-trials-enhanced-data-integrity-and-digital-health-integration 2025-03-01T16:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-can-2409-shows-dramatic-survival-benefit-in-phase-2-pancreatic-cancer-trial 2025-03-01T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-can-2409-shows-dramatic-survival-benefit-in-phase-2-pancreatic-cancer-trial 2025-03-01T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/climate-change-extends-pollen-seasons-prompting-new-approaches-to-allergy-management 2025-03-01T10:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/climate-change-extends-pollen-seasons-prompting-new-approaches-to-allergy-management 2025-03-01T10:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/high-hdl-cholesterol-linked-to-increased-glaucoma-risk-in-older-adults-large-uk-study-finds 2025-03-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-hdl-cholesterol-linked-to-increased-glaucoma-risk-in-older-adults-large-uk-study-finds 2025-03-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medtronic-s-groundbreaking-adaptive-dbs-system-for-parkinson-s-disease 2025-03-01T05:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-groundbreaking-adaptive-dbs-system-for-parkinson-s-disease 2025-03-01T05:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/steakholder-foods-secures-9-25m-in-strategic-funding-to-advance-3d-printed-alternative-proteins 2025-03-01T02:02:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/steakholder-foods-secures-9-25m-in-strategic-funding-to-advance-3d-printed-alternative-proteins 2025-03-01T02:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/adagio-medical-restructures-operations-to-focus-on-pivotal-vt-cryoablation-trial 2025-03-01T01:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adagio-medical-restructures-operations-to-focus-on-pivotal-vt-cryoablation-trial 2025-03-01T01:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-eliminates-pharmacist-blood-test-verification-requirement-for-clozapine-dispensing 2025-03-01T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-eliminates-pharmacist-blood-test-verification-requirement-for-clozapine-dispensing 2025-03-01T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/mission-therapeutics-discontinues-preclinical-operations-to-focus-on-advanced-clinical-programs 2025-03-01T01:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mission-therapeutics-discontinues-preclinical-operations-to-focus-on-advanced-clinical-programs 2025-03-01T01:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/nice-reverses-decision-approves-sobi-s-altuvoct-for-hemophilia-a-treatment-in-england 2025-03-01T01:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-reverses-decision-approves-sobi-s-altuvoct-for-hemophilia-a-treatment-in-england 2025-03-01T01:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-new-guidance-on-controlled-correspondence-for-generic-drug-development 2025-03-01T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-new-guidance-on-controlled-correspondence-for-generic-drug-development 2025-03-01T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-march-pipeline-novel-therapies-target-hemophilia-heart-disease-and-rare-conditions 2025-03-01T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-march-pipeline-novel-therapies-target-hemophilia-heart-disease-and-rare-conditions 2025-03-01T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-expands-digital-health-partnership-with-evidation-to-advance-patient-generated-data-analytics 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-expands-digital-health-partnership-with-evidation-to-advance-patient-generated-data-analytics 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/navigating-regulatory-hurdles-key-challenges-for-medtech-startups-in-device-development 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigating-regulatory-hurdles-key-challenges-for-medtech-startups-in-device-development 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-rejects-takeda-s-fruzaqla-for-advanced-colorectal-cancer-due-to-cost-concerns 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-rejects-takeda-s-fruzaqla-for-advanced-colorectal-cancer-due-to-cost-concerns 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rocket-pharmaceuticals-gene-therapy-shows-promise-in-early-danon-disease-trial 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocket-pharmaceuticals-gene-therapy-shows-promise-in-early-danon-disease-trial 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-zevtera-for-s-aureus-bacteremia-marking-first-new-treatment-in-15-years 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-zevtera-for-s-aureus-bacteremia-marking-first-new-treatment-in-15-years 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-vitrakvi-makes-history-as-first-tumor-agnostic-drug-approved-in-european-union 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-vitrakvi-makes-history-as-first-tumor-agnostic-drug-approved-in-european-union 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/expert-insights-navigating-the-complex-landscape-of-biosimilars-and-biobetters-development 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-insights-navigating-the-complex-landscape-of-biosimilars-and-biobetters-development 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/seismic-therapeutic-s-novel-ige-protease-s-8484-shows-promise-in-preclinical-allergic-disease-studies 2025-02-28T23:02:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seismic-therapeutic-s-novel-ige-protease-s-8484-shows-promise-in-preclinical-allergic-disease-studies 2025-02-28T23:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/kiyatec-secures-cap-accreditation-and-ny-state-approval-for-revolutionary-3d-cancer-diagnostic-platform 2025-02-28T23:01:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiyatec-secures-cap-accreditation-and-ny-state-approval-for-revolutionary-3d-cancer-diagnostic-platform 2025-02-28T23:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/avirmax-biopharma-advances-novel-triple-gene-therapy-for-dry-amd-with-ind-enabling-studies 2025-02-28T22:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avirmax-biopharma-advances-novel-triple-gene-therapy-for-dry-amd-with-ind-enabling-studies 2025-02-28T22:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-advances-dmd-treatment-program-despite-price-target-adjustment 2025-02-28T22:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-advances-dmd-treatment-program-despite-price-target-adjustment 2025-02-28T22:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-s-lomecel-b-nears-full-enrollment-in-pivotal-hlhs-trial-shows-promise-in-pediatric-heart-disease 2025-02-28T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longeveron-s-lomecel-b-nears-full-enrollment-in-pivotal-hlhs-trial-shows-promise-in-pediatric-heart-disease 2025-02-28T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/bukwang-pharmaceutical-introduces-novel-combination-therapy-for-alzheimer-s-disease 2025-02-28T22:33:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bukwang-pharmaceutical-introduces-novel-combination-therapy-for-alzheimer-s-disease 2025-02-28T22:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/darzalex-r-subcutaneous-regimen-receives-chmp-backing-for-newly-diagnosed-multiple-myeloma-treatment 2025-02-28T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/darzalex-r-subcutaneous-regimen-receives-chmp-backing-for-newly-diagnosed-multiple-myeloma-treatment 2025-02-28T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/immune-onc-initiates-phase-i-trial-of-novel-io-108-antibody-for-advanced-hepatocellular-carcinoma 2025-02-28T22:32:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-onc-initiates-phase-i-trial-of-novel-io-108-antibody-for-advanced-hepatocellular-carcinoma 2025-02-28T22:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/stelara-r-receives-chmp-backing-for-pediatric-crohn-s-disease-treatment-in-europe 2025-02-28T22:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stelara-r-receives-chmp-backing-for-pediatric-crohn-s-disease-treatment-in-europe 2025-02-28T22:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-and-envveno-medical-each-file-100m-mixed-securities-shelf 2025-02-28T22:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serina-therapeutics-and-envveno-medical-each-file-100m-mixed-securities-shelf 2025-02-28T22:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-abbvie-s-rinvoq-for-giant-cell-arteritis-treatment-in-adults 2025-02-28T19:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-abbvie-s-rinvoq-for-giant-cell-arteritis-treatment-in-adults 2025-02-28T19:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-therapeutics-essential-tremor-drug-faces-setback-in-phase-3-interim-analysis 2025-02-28T19:34:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-therapeutics-essential-tremor-drug-faces-setback-in-phase-3-interim-analysis 2025-02-28T19:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/sinucleanse-nasal-wash-system-recalled-nationwide-due-to-potentially-fatal-bacterial-contamination 2025-02-28T19:34:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sinucleanse-nasal-wash-system-recalled-nationwide-due-to-potentially-fatal-bacterial-contamination 2025-02-28T19:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/koite-health-secures-us-patent-for-technology-enhancing-antibiotic-efficacy-against-superbugs 2025-02-28T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/koite-health-secures-us-patent-for-technology-enhancing-antibiotic-efficacy-against-superbugs 2025-02-28T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-approves-revolutionary-weekly-treatment-for-severe-haemophilia-a-at-ps510000-per-year 2025-02-28T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-approves-revolutionary-weekly-treatment-for-severe-haemophilia-a-at-ps510000-per-year 2025-02-28T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/ema-and-who-launch-global-pilot-program-to-streamline-drug-regulation-changes 2025-02-28T19:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-and-who-launch-global-pilot-program-to-streamline-drug-regulation-changes 2025-02-28T19:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-regeneron-and-novartis-novel-therapies-ahead-of-fda-decisions 2025-02-28T19:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-regeneron-and-novartis-novel-therapies-ahead-of-fda-decisions 2025-02-28T19:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/dexmedetomidine-shows-no-benefit-in-treating-refractory-septic-shock-pilot-study-finds 2025-02-28T19:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dexmedetomidine-shows-no-benefit-in-treating-refractory-septic-shock-pilot-study-finds 2025-02-28T19:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/cholesterol-drug-fenofibrate-shows-promise-in-treating-hpv-related-cancers 2025-02-28T19:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cholesterol-drug-fenofibrate-shows-promise-in-treating-hpv-related-cancers 2025-02-28T19:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/ancient-viral-dna-awakens-to-aid-immune-fight-against-kidney-cancer 2025-02-28T19:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ancient-viral-dna-awakens-to-aid-immune-fight-against-kidney-cancer 2025-02-28T19:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/bambusa-therapeutics-initiates-phase-i-trial-of-novel-bispecific-antibody-for-alzheimer-s-disease 2025-02-28T19:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bambusa-therapeutics-initiates-phase-i-trial-of-novel-bispecific-antibody-for-alzheimer-s-disease 2025-02-28T19:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/adocia-secures-eur9-7-million-private-placement-to-advance-diabetes-and-obesity-pipeline-through-q2-2026 2025-02-28T19:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adocia-secures-eur9-7-million-private-placement-to-advance-diabetes-and-obesity-pipeline-through-q2-2026 2025-02-28T19:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-enters-1-6b-molecular-glue-partnership-with-magnet-biomedicine-for-cancer-drug-development 2025-02-28T18:01:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-enters-1-6b-molecular-glue-partnership-with-magnet-biomedicine-for-cancer-drug-development 2025-02-28T18:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-s-phase-3-essential-tremor-drug-trial-faces-futility-concerns-shares-plunge-40 2025-02-28T17:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-s-phase-3-essential-tremor-drug-trial-faces-futility-concerns-shares-plunge-40 2025-02-28T17:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-oncology-secures-450m-spac-deal-to-advance-kras-inhibitor-pipeline 2025-02-28T17:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-oncology-secures-450m-spac-deal-to-advance-kras-inhibitor-pipeline 2025-02-28T17:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-pharmaceuticals-reports-18-revenue-growth-expands-into-weight-loss-and-biosimilar-markets 2025-02-28T17:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-pharmaceuticals-reports-18-revenue-growth-expands-into-weight-loss-and-biosimilar-markets 2025-02-28T17:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/danish-startup-fuse-vectors-secures-5-2m-to-revolutionize-gene-therapy-production 2025-02-28T16:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danish-startup-fuse-vectors-secures-5-2m-to-revolutionize-gene-therapy-production 2025-02-28T16:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/alumis-to-present-52-week-phase-2-data-for-novel-tyk2-inhibitor-in-psoriasis-at-aad-2025 2025-02-28T16:35:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alumis-to-present-52-week-phase-2-data-for-novel-tyk2-inhibitor-in-psoriasis-at-aad-2025 2025-02-28T16:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/three-year-data-shows-sustained-benefits-of-car-t-cell-therapy-in-relapsed-refractory-large-b-cell-lymphoma 2025-02-28T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-year-data-shows-sustained-benefits-of-car-t-cell-therapy-in-relapsed-refractory-large-b-cell-lymphoma 2025-02-28T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/silence-therapeutics-halts-phase-iii-development-of-zerlasiran-seeks-partnership-for-cardiovascular-drug 2025-02-28T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silence-therapeutics-halts-phase-iii-development-of-zerlasiran-seeks-partnership-for-cardiovascular-drug 2025-02-28T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-acquires-solventum-s-filtration-business-in-4-1-billion-deal 2025-02-28T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-acquires-solventum-s-filtration-business-in-4-1-billion-deal 2025-02-28T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotechnology-secures-11-million-in-latest-funding-round 2025-02-28T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pds-biotechnology-secures-11-million-in-latest-funding-round 2025-02-28T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/ema-committee-recommends-new-therapies-including-vyjuvek-for-rare-skin-disease-and-expands-existing-drug-indications 2025-02-28T16:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-committee-recommends-new-therapies-including-vyjuvek-for-rare-skin-disease-and-expands-existing-drug-indications 2025-02-28T16:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-drug-reviews-face-potential-halt-amid-march-2025-government-shutdown-risk 2025-02-28T16:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-drug-reviews-face-potential-halt-amid-march-2025-government-shutdown-risk 2025-02-28T16:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/phase-4-kinect-pro-trial-shows-ingrezza-significantly-improves-quality-of-life-in-tardive-dyskinesia-patients 2025-02-28T16:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-4-kinect-pro-trial-shows-ingrezza-significantly-improves-quality-of-life-in-tardive-dyskinesia-patients 2025-02-28T16:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antibiotic-gepotidacin-shows-promise-for-drug-resistant-utis-awaits-fda-review 2025-02-28T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-antibiotic-gepotidacin-shows-promise-for-drug-resistant-utis-awaits-fda-review 2025-02-28T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/bambusa-therapeutics-initiates-phase-1-trial-of-novel-bispecific-antibody-bbt001-for-atopic-dermatitis 2025-02-28T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bambusa-therapeutics-initiates-phase-1-trial-of-novel-bispecific-antibody-bbt001-for-atopic-dermatitis 2025-02-28T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/celldex-advances-barzolvolimab-phase-3-program-in-chronic-urticaria-with-strong-pipeline-progress 2025-02-28T15:03:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celldex-advances-barzolvolimab-phase-3-program-in-chronic-urticaria-with-strong-pipeline-progress 2025-02-28T15:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-partners-with-sciclone-to-expand-tasurgratinib-access-in-greater-china-for-biliary-tract-cancer-treatment 2025-02-28T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-partners-with-sciclone-to-expand-tasurgratinib-access-in-greater-china-for-biliary-tract-cancer-treatment 2025-02-28T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/dfp-10917-and-venetoclax-combination-trial-advances-to-phase-ii-for-aml-treatment 2025-02-28T14:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dfp-10917-and-venetoclax-combination-trial-advances-to-phase-ii-for-aml-treatment 2025-02-28T14:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-expert-outlines-key-strategies-to-enhance-shared-decision-making-in-breast-cancer-care 2025-02-28T14:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-expert-outlines-key-strategies-to-enhance-shared-decision-making-in-breast-cancer-care 2025-02-28T14:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/nasal-spray-shows-promise-in-treating-traumatic-brain-injury-reducing-inflammation 2025-02-28T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasal-spray-shows-promise-in-treating-traumatic-brain-injury-reducing-inflammation 2025-02-28T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-unveils-major-overhaul-of-pharmaceutical-patent-extension-system-with-centralized-spc-filing 2025-02-28T13:34:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-unveils-major-overhaul-of-pharmaceutical-patent-extension-system-with-centralized-spc-filing 2025-02-28T13:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-rinvoq-receives-positive-chmp-opinion-for-giant-cell-arteritis-treatment 2025-02-28T13:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-rinvoq-receives-positive-chmp-opinion-for-giant-cell-arteritis-treatment 2025-02-28T13:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ind-for-fp008-a-novel-pd-1xil-10m-fusion-protein-for-resistant-solid-tumors 2025-02-28T13:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ind-for-fp008-a-novel-pd-1xil-10m-fusion-protein-for-resistant-solid-tumors 2025-02-28T13:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/owkin-launches-atlantis-ai-powered-patient-data-mining-initiative-across-20-global-healthcare-centers 2025-02-28T13:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/owkin-launches-atlantis-ai-powered-patient-data-mining-initiative-across-20-global-healthcare-centers 2025-02-28T13:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/prorx-pharma-doubles-facility-size-to-combat-critical-drug-shortages 2025-02-28T13:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prorx-pharma-doubles-facility-size-to-combat-critical-drug-shortages 2025-02-28T13:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/global-stroke-clinical-trials-landscape-analysis-reveals-key-market-trends-for-2025 2025-02-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-stroke-clinical-trials-landscape-analysis-reveals-key-market-trends-for-2025 2025-02-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/nk-cell-therapy-market-poised-for-significant-growth-with-innovative-pipeline-developments 2025-02-28T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nk-cell-therapy-market-poised-for-significant-growth-with-innovative-pipeline-developments 2025-02-28T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-gene-therapy-trial-launches-for-rare-muscle-disorder-fshd 2025-02-28T11:57:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-gene-therapy-trial-launches-for-rare-muscle-disorder-fshd 2025-02-28T11:57:45+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-acquires-global-rights-to-cenerimod-for-autoimmune-diseases-with-10m-nxera-deal 2025-02-28T11:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-acquires-global-rights-to-cenerimod-for-autoimmune-diseases-with-10m-nxera-deal 2025-02-28T11:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/astria-therapeutics-launches-phase-iii-trial-for-novel-hereditary-angioedema-treatment 2025-02-28T10:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astria-therapeutics-launches-phase-iii-trial-for-novel-hereditary-angioedema-treatment 2025-02-28T10:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/renovaro-and-biosymetrics-announce-merger-to-accelerate-ai-driven-drug-discovery-and-biomarker-development 2025-02-28T10:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovaro-and-biosymetrics-announce-merger-to-accelerate-ai-driven-drug-discovery-and-biomarker-development 2025-02-28T10:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-partners-with-gabbi-to-expand-hereditary-cancer-risk-testing-access 2025-02-28T10:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-partners-with-gabbi-to-expand-hereditary-cancer-risk-testing-access 2025-02-28T10:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/emavusertib-shows-promise-in-flt3-mutated-aml-patients-resistant-to-prior-therapies 2025-02-28T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emavusertib-shows-promise-in-flt3-mutated-aml-patients-resistant-to-prior-therapies 2025-02-28T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-partners-with-holling-bio-pharma-to-launch-daridorexant-for-insomnia-in-taiwan 2025-02-28T10:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nxera-pharma-partners-with-holling-bio-pharma-to-launch-daridorexant-for-insomnia-in-taiwan 2025-02-28T10:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-expands-global-footprint-with-launch-of-novel-diabetes-and-obesity-drug-in-uk-market 2025-02-28T10:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-expands-global-footprint-with-launch-of-novel-diabetes-and-obesity-drug-in-uk-market 2025-02-28T10:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-pioneers-first-generic-liraglutide-launch-in-uk-for-diabetes-and-obesity-treatment 2025-02-28T10:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-pioneers-first-generic-liraglutide-launch-in-uk-for-diabetes-and-obesity-treatment 2025-02-28T10:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-pharmaceuticals-redirects-mirivadelgat-development-to-ph-ild-following-fanconi-anemia-trial-challenges 2025-02-28T10:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-redirects-mirivadelgat-development-to-ph-ild-following-fanconi-anemia-trial-challenges 2025-02-28T10:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/pacific-edge-s-cxbladder-triage-test-incorporated-into-aua-microhematuria-guidelines-as-only-biomarker-with-grade-a-evidence 2025-02-28T10:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacific-edge-s-cxbladder-triage-test-incorporated-into-aua-microhematuria-guidelines-as-only-biomarker-with-grade-a-evidence 2025-02-28T10:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-novel-drug-shows-promise-in-advanced-pancreatic-cancer-treatment 2025-02-28T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-novel-drug-shows-promise-in-advanced-pancreatic-cancer-treatment 2025-02-28T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-partners-with-eleison-to-optimize-phase-3-pancreatic-cancer-trial-using-ai-analytics 2025-02-28T09:14:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bullfrog-ai-partners-with-eleison-to-optimize-phase-3-pancreatic-cancer-trial-using-ai-analytics 2025-02-28T09:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-promise-camrelizumab-plus-chemotherapy-effective-for-advanced-nasopharyngeal-cancer-in-non-endemic-regions 2025-02-28T09:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-shows-promise-camrelizumab-plus-chemotherapy-effective-for-advanced-nasopharyngeal-cancer-in-non-endemic-regions 2025-02-28T09:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/phase-4-trial-explores-ozanimod-switch-for-stable-ms-patients-on-anti-cd20-therapy 2025-02-28T09:13:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-4-trial-explores-ozanimod-switch-for-stable-ms-patients-on-anti-cd20-therapy 2025-02-28T09:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-five-groundbreaking-treatments-for-ultra-rare-diseases-in-recent-months 2025-02-28T09:12:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-five-groundbreaking-treatments-for-ultra-rare-diseases-in-recent-months 2025-02-28T09:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/experts-highlight-patient-engagement-and-emerging-biomarkers-in-cll-treatment-decision-making 2025-02-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-highlight-patient-engagement-and-emerging-biomarkers-in-cll-treatment-decision-making 2025-02-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medigene-and-epimab-partner-to-develop-novel-tcr-guided-t-cell-engagers-for-solid-tumors 2025-02-28T06:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medigene-and-epimab-partner-to-develop-novel-tcr-guided-t-cell-engagers-for-solid-tumors 2025-02-28T06:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-polycystic-kidney-disease-clinical-trials-landscape-mapped-in-comprehensive-2025-review 2025-02-28T05:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-polycystic-kidney-disease-clinical-trials-landscape-mapped-in-comprehensive-2025-review 2025-02-28T05:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-global-clinical-trials-report-reveals-comprehensive-landscape-of-ewing-sarcoma-research-in-2025 2025-02-28T05:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-global-clinical-trials-report-reveals-comprehensive-landscape-of-ewing-sarcoma-research-in-2025 2025-02-28T05:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-awards-three-research-grants-to-advance-gastrointestinal-cancer-treatments-with-taiho-oncology 2025-02-28T05:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-awards-three-research-grants-to-advance-gastrointestinal-cancer-treatments-with-taiho-oncology 2025-02-28T05:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/physical-performance-tests-predict-icans-risk-and-survival-in-car-t-cell-therapy-for-nhl 2025-02-28T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physical-performance-tests-predict-icans-risk-and-survival-in-car-t-cell-therapy-for-nhl 2025-02-28T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-orthonovis-s-novel-bps-wrist-fracture-system 2025-02-28T05:02:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-orthonovis-s-novel-bps-wrist-fracture-system 2025-02-28T05:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-ldt-regulation-faces-uncertainty-as-may-2025-compliance-deadline-approaches 2025-02-28T04:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-ldt-regulation-faces-uncertainty-as-may-2025-compliance-deadline-approaches 2025-02-28T04:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-s-phase-iii-trial-advances-apitegromab-development-for-spinal-muscular-atrophy 2025-02-28T04:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-s-phase-iii-trial-advances-apitegromab-development-for-spinal-muscular-atrophy 2025-02-28T04:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/uk-faces-growing-challenges-in-access-to-rare-disease-medicines-despite-recent-approvals 2025-02-28T04:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-faces-growing-challenges-in-access-to-rare-disease-medicines-despite-recent-approvals 2025-02-28T04:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-s-dna-plasmid-vaccine-shows-promising-safety-and-immune-response-in-clinical-trial 2025-02-28T04:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imunon-s-dna-plasmid-vaccine-shows-promising-safety-and-immune-response-in-clinical-trial 2025-02-28T04:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/prestige-af-trial-doacs-show-mixed-results-in-preventing-strokes-for-ich-survivors-with-atrial-fibrillation 2025-02-28T04:32:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prestige-af-trial-doacs-show-mixed-results-in-preventing-strokes-for-ich-survivors-with-atrial-fibrillation 2025-02-28T04:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/uk-experts-call-for-centralized-genomic-database-to-accelerate-rare-disease-trial-recruitment 2025-02-28T03:18:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-experts-call-for-centralized-genomic-database-to-accelerate-rare-disease-trial-recruitment 2025-02-28T03:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/afynia-secures-5m-to-advance-novel-blood-test-for-faster-endometriosis-diagnosis 2025-02-28T02:31:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/afynia-secures-5m-to-advance-novel-blood-test-for-faster-endometriosis-diagnosis 2025-02-28T02:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/soleno-therapeutics-advances-toward-potential-dccr-approval-for-prader-willi-syndrome-with-strong-financial-position 2025-02-28T02:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soleno-therapeutics-advances-toward-potential-dccr-approval-for-prader-willi-syndrome-with-strong-financial-position 2025-02-28T02:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/testosterone-recovery-after-adt-shows-46-lower-mortality-risk-in-high-risk-prostate-cancer-study 2025-02-28T01:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/testosterone-recovery-after-adt-shows-46-lower-mortality-risk-in-high-risk-prostate-cancer-study 2025-02-28T01:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-tandem-s-control-iq-algorithm-for-type-2-diabetes-management 2025-02-28T01:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-tandem-s-control-iq-algorithm-for-type-2-diabetes-management 2025-02-28T01:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/higher-dose-fractionated-reirradiation-shows-promise-in-recurrent-high-grade-glioma-treatment 2025-02-28T01:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/higher-dose-fractionated-reirradiation-shows-promise-in-recurrent-high-grade-glioma-treatment 2025-02-28T01:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/early-biological-therapy-shows-promise-in-young-psoriasis-patients-belgian-study-supports-step-down-approach 2025-02-28T01:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-biological-therapy-shows-promise-in-young-psoriasis-patients-belgian-study-supports-step-down-approach 2025-02-28T01:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/calliper-trial-in-progressive-ms-shows-distinct-patient-profile-with-lower-inflammatory-activity 2025-02-28T01:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calliper-trial-in-progressive-ms-shows-distinct-patient-profile-with-lower-inflammatory-activity 2025-02-28T01:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/novel-triple-immunotherapy-approach-shows-promise-in-glioblastoma-treatment 2025-02-28T01:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-triple-immunotherapy-approach-shows-promise-in-glioblastoma-treatment 2025-02-28T01:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-partners-with-pathomiq-to-advance-ai-powered-prostate-cancer-prognosis-platform 2025-02-28T01:31:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-partners-with-pathomiq-to-advance-ai-powered-prostate-cancer-prognosis-platform 2025-02-28T01:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-and-alteogen-partner-on-300m-deal-to-develop-subcutaneous-enhertu 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-and-alteogen-partner-on-300m-deal-to-develop-subcutaneous-enhertu 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/latin-america-s-pharmaceutical-market-access-challenges-and-opportunities-in-emerging-markets 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latin-america-s-pharmaceutical-market-access-challenges-and-opportunities-in-emerging-markets 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/swissmedic-approves-46-new-active-substances-in-2024-marking-12-increase-in-drug-authorizations 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swissmedic-approves-46-new-active-substances-in-2024-marking-12-increase-in-drug-authorizations 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/topical-drug-delivery-market-set-to-reach-454-93-billion-by-2031-as-targeted-delivery-technologies-advance 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topical-drug-delivery-market-set-to-reach-454-93-billion-by-2031-as-targeted-delivery-technologies-advance 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/work-medical-and-shanghai-chartwell-form-strategic-alliance-to-advance-high-end-medical-technologies 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/work-medical-and-shanghai-chartwell-form-strategic-alliance-to-advance-high-end-medical-technologies 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-soliris-for-refractory-myasthenia-gravis-first-new-treatment-in-60-years 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-soliris-for-refractory-myasthenia-gravis-first-new-treatment-in-60-years 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-ceo-calls-for-pharma-industry-reputation-rebuild-amid-public-trust-crisis 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-ceo-calls-for-pharma-industry-reputation-rebuild-amid-public-trust-crisis 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-initiates-review-of-roche-s-monthly-injectable-crovalimab-for-rare-blood-disorder-pnh 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-initiates-review-of-roche-s-monthly-injectable-crovalimab-for-rare-blood-disorder-pnh 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/digital-revolution-reshapes-healthcare-rise-of-the-patient-of-the-future-drives-innovation 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-revolution-reshapes-healthcare-rise-of-the-patient-of-the-future-drives-innovation 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-review-of-lerodalcibep-for-ldl-cholesterol-reduction 2025-02-27T23:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-review-of-lerodalcibep-for-ldl-cholesterol-reduction 2025-02-27T23:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/breathe-biomedical-initiates-major-clinical-trial-for-innovative-breast-cancer-breath-test 2025-02-27T23:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breathe-biomedical-initiates-major-clinical-trial-for-innovative-breast-cancer-breath-test 2025-02-27T23:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/ribociclib-letrozole-combo-shows-promising-24-response-rate-in-low-grade-serous-ovarian-cancer-trial 2025-02-27T22:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribociclib-letrozole-combo-shows-promising-24-response-rate-in-low-grade-serous-ovarian-cancer-trial 2025-02-27T22:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/estee-lauder-partners-with-serpin-pharma-to-develop-anti-inflammatory-skincare-technology 2025-02-27T22:34:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/estee-lauder-partners-with-serpin-pharma-to-develop-anti-inflammatory-skincare-technology 2025-02-27T22:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-arcuro-medical-s-superball-rc-system-for-rotator-cuff-repair-enhancement 2025-02-27T22:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-arcuro-medical-s-superball-rc-system-for-rotator-cuff-repair-enhancement 2025-02-27T22:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-announces-27-billion-investment-in-four-new-us-manufacturing-sites 2025-02-27T22:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-announces-27-billion-investment-in-four-new-us-manufacturing-sites 2025-02-27T22:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-odactra-r-approval-for-house-dust-mite-allergy-treatment-to-include-young-children 2025-02-27T22:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-odactra-r-approval-for-house-dust-mite-allergy-treatment-to-include-young-children 2025-02-27T22:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/structure-therapeutics-advances-oral-obesity-drug-programs-with-completed-enrollment-in-key-aleniglipron-trials 2025-02-27T22:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structure-therapeutics-advances-oral-obesity-drug-programs-with-completed-enrollment-in-key-aleniglipron-trials 2025-02-27T22:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/pharmala-to-develop-novel-mdma-dosage-form-for-military-ptsd-trial-at-ut-health-san-antonio 2025-02-27T22:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmala-to-develop-novel-mdma-dosage-form-for-military-ptsd-trial-at-ut-health-san-antonio 2025-02-27T22:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/across-global-alliance-adopts-wemedoo-s-oomnia-platform-to-transform-global-clinical-trial-management 2025-02-27T22:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/across-global-alliance-adopts-wemedoo-s-oomnia-platform-to-transform-global-clinical-trial-management 2025-02-27T22:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-rare-disease-research-primary-data-collection-studies-emerge-as-critical-tool-for-real-world-evidence 2025-02-27T22:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-rare-disease-research-primary-data-collection-studies-emerge-as-critical-tool-for-real-world-evidence 2025-02-27T22:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/validose-secures-2m-pre-seed-funding-to-transform-clinical-trial-adherence-with-smart-drug-delivery-platform 2025-02-27T22:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/validose-secures-2m-pre-seed-funding-to-transform-clinical-trial-adherence-with-smart-drug-delivery-platform 2025-02-27T22:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-rare-disease-research-how-mrna-technology-and-synthetic-control-arms-are-transforming-clinical-trials 2025-02-27T21:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-rare-disease-research-how-mrna-technology-and-synthetic-control-arms-are-transforming-clinical-trials 2025-02-27T21:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-ozempic-and-wegovy-from-shortage-list-sparking-legal-challenge-from-compounding-groups 2025-02-27T20:01:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-ozempic-and-wegovy-from-shortage-list-sparking-legal-challenge-from-compounding-groups 2025-02-27T20:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-superior-immunogenicity-of-rabies-booster-after-zagreb-regimen-compared-to-essen-protocol 2025-02-27T19:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-superior-immunogenicity-of-rabies-booster-after-zagreb-regimen-compared-to-essen-protocol 2025-02-27T19:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/usda-grants-conditional-approval-for-zoetis-avian-influenza-vaccine 2025-02-27T19:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usda-grants-conditional-approval-for-zoetis-avian-influenza-vaccine 2025-02-27T19:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/ema-evaluates-fast-track-status-for-three-novel-therapeutics-from-scholar-insmed-and-soleno 2025-02-27T19:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-evaluates-fast-track-status-for-three-novel-therapeutics-from-scholar-insmed-and-soleno 2025-02-27T19:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cancels-critical-flu-vaccine-advisory-meeting-raising-production-timeline-concerns 2025-02-27T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-cancels-critical-flu-vaccine-advisory-meeting-raising-production-timeline-concerns 2025-02-27T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/wegovy-s-market-dominance-grows-with-expanded-cardiovascular-indication-and-strong-clinical-results 2025-02-27T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wegovy-s-market-dominance-grows-with-expanded-cardiovascular-indication-and-strong-clinical-results 2025-02-27T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-exscientia-merger-signals-new-era-in-ai-driven-drug-discovery 2025-02-27T19:33:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-exscientia-merger-signals-new-era-in-ai-driven-drug-discovery 2025-02-27T19:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/ira-price-controls-threaten-u-s-small-molecule-drug-innovation-and-clinical-research 2025-02-27T19:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ira-price-controls-threaten-u-s-small-molecule-drug-innovation-and-clinical-research 2025-02-27T19:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-biopharma-goes-public-on-nasdaq-through-spac-merger-to-advance-fast-absorbing-aspirin-development 2025-02-27T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspire-biopharma-goes-public-on-nasdaq-through-spac-merger-to-advance-fast-absorbing-aspirin-development 2025-02-27T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-inspection-of-emcure-s-api-facility-results-in-form-483-relonchem-gains-uk-approval-for-pain-relief-combination 2025-02-27T19:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-inspection-of-emcure-s-api-facility-results-in-form-483-relonchem-gains-uk-approval-for-pain-relief-combination 2025-02-27T19:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-companies-advance-novel-seizure-treatments-with-promising-pipeline-developments 2025-02-27T19:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmaceutical-companies-advance-novel-seizure-treatments-with-promising-pipeline-developments 2025-02-27T19:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/iavi-and-biofabri-launch-phase-2a-trial-of-novel-tuberculosis-vaccine-in-adults-and-adolescents 2025-02-27T19:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iavi-and-biofabri-launch-phase-2a-trial-of-novel-tuberculosis-vaccine-in-adults-and-adolescents 2025-02-27T19:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-receives-novel-outlast-enhanced-car-t-therapy-for-advanced-kidney-cancer 2025-02-27T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-receives-novel-outlast-enhanced-car-t-therapy-for-advanced-kidney-cancer 2025-02-27T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/retinalgenix-launches-revolutionary-remote-ocular-monitoring-system-for-early-disease-detection 2025-02-27T19:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retinalgenix-launches-revolutionary-remote-ocular-monitoring-system-for-early-disease-detection 2025-02-27T19:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-reviews-moderna-s-590m-bird-flu-vaccine-contract-amid-market-uncertainty 2025-02-27T19:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-reviews-moderna-s-590m-bird-flu-vaccine-contract-amid-market-uncertainty 2025-02-27T19:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-sclerosis-trial-analysis-comorbidities-increase-risk-of-treatment-discontinuation-and-adverse-events 2025-02-27T18:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiple-sclerosis-trial-analysis-comorbidities-increase-risk-of-treatment-discontinuation-and-adverse-events 2025-02-27T18:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-pivots-business-model-shifts-focus-from-vaccine-development-to-technology-licensing 2025-02-27T18:01:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-pivots-business-model-shifts-focus-from-vaccine-development-to-technology-licensing 2025-02-27T18:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-partners-with-brainomix-to-advance-ai-powered-stroke-care-solutions 2025-02-27T16:35:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-partners-with-brainomix-to-advance-ai-powered-stroke-care-solutions 2025-02-27T16:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/brainomix-and-medtronic-form-strategic-alliance-to-transform-stroke-care-with-ai-technology 2025-02-27T16:35:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainomix-and-medtronic-form-strategic-alliance-to-transform-stroke-care-with-ai-technology 2025-02-27T16:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/zevra-therapeutics-secures-150m-deal-for-rare-pediatric-disease-priority-review-voucher 2025-02-27T16:35:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zevra-therapeutics-secures-150m-deal-for-rare-pediatric-disease-priority-review-voucher 2025-02-27T16:35:10+00:00 hourly 0.9 https://trial.medpath.com/news/hbm-alpha-therapeutics-secures-395m-licensing-deal-for-novel-cah-treatment 2025-02-27T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hbm-alpha-therapeutics-secures-395m-licensing-deal-for-novel-cah-treatment 2025-02-27T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/tiximed-reports-positive-safety-data-from-first-cohort-in-phase-1-trial-of-novel-type-1-diabetes-drug-tix100 2025-02-27T16:34:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiximed-reports-positive-safety-data-from-first-cohort-in-phase-1-trial-of-novel-type-1-diabetes-drug-tix100 2025-02-27T16:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/usaid-funding-freeze-disrupts-critical-hiv-vaccine-development-in-africa 2025-02-27T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usaid-funding-freeze-disrupts-critical-hiv-vaccine-development-in-africa 2025-02-27T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-avb-114-novel-cell-therapy-for-crohn-s-perianal-fistulas 2025-02-27T16:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-avb-114-novel-cell-therapy-for-crohn-s-perianal-fistulas 2025-02-27T16:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/major-advances-in-angioedema-pipeline-intellia-s-gene-therapy-enters-phase-3-as-multiple-companies-race-for-novel-treatments 2025-02-27T16:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-advances-in-angioedema-pipeline-intellia-s-gene-therapy-enters-phase-3-as-multiple-companies-race-for-novel-treatments 2025-02-27T16:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-google-pixel-watch-3-s-novel-pulse-detection-feature-for-critical-health-monitoring 2025-02-27T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-google-pixel-watch-3-s-novel-pulse-detection-feature-for-critical-health-monitoring 2025-02-27T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/canopy-growth-expands-german-medical-cannabis-portfolio-with-tweed-brand-launch 2025-02-27T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canopy-growth-expands-german-medical-cannabis-portfolio-with-tweed-brand-launch 2025-02-27T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-endorses-hlb-s-cam-rivo-for-first-line-liver-cancer-treatment-ahead-of-fda-decision 2025-02-27T16:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esmo-endorses-hlb-s-cam-rivo-for-first-line-liver-cancer-treatment-ahead-of-fda-decision 2025-02-27T16:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/bevacizumab-biosimilars-demonstrate-comparable-efficacy-and-safety-profile-to-avastin-in-advanced-nsclc-study 2025-02-27T16:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bevacizumab-biosimilars-demonstrate-comparable-efficacy-and-safety-profile-to-avastin-in-advanced-nsclc-study 2025-02-27T16:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/vapor-2-trial-completes-enrollment-testing-novel-water-vapor-ablation-device-for-prostate-cancer 2025-02-27T16:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vapor-2-trial-completes-enrollment-testing-novel-water-vapor-ablation-device-for-prostate-cancer 2025-02-27T16:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/virpax-pharmaceuticals-reports-successful-human-trial-of-molecular-envelope-technology-with-no-severe-adverse-events 2025-02-27T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virpax-pharmaceuticals-reports-successful-human-trial-of-molecular-envelope-technology-with-no-severe-adverse-events 2025-02-27T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/adagene-initiates-phase-2-trial-of-novel-ctla-4-inhibitor-in-early-stage-colorectal-cancer 2025-02-27T14:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adagene-initiates-phase-2-trial-of-novel-ctla-4-inhibitor-in-early-stage-colorectal-cancer 2025-02-27T14:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-visumax-800-with-smile-pro-receives-nmpa-approval-for-laser-vision-correction-in-china 2025-02-27T14:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeiss-visumax-800-with-smile-pro-receives-nmpa-approval-for-laser-vision-correction-in-china 2025-02-27T14:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/cost-effectiveness-analysis-critical-for-optimizing-car-t-and-bispecific-therapies-in-blood-cancers 2025-02-27T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cost-effectiveness-analysis-critical-for-optimizing-car-t-and-bispecific-therapies-in-blood-cancers 2025-02-27T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/tango-therapeutics-tng462-receives-orphan-drug-status-for-pancreatic-cancer-as-company-advances-prmt5-inhibitor-programs 2025-02-27T14:01:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tango-therapeutics-tng462-receives-orphan-drug-status-for-pancreatic-cancer-as-company-advances-prmt5-inhibitor-programs 2025-02-27T14:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-generic-epinephrine-injection-with-180-day-exclusivity 2025-02-27T13:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-launches-generic-epinephrine-injection-with-180-day-exclusivity 2025-02-27T13:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/aspargo-labs-strengthens-leadership-team-with-appointment-of-former-amgen-regulatory-expert-as-cro 2025-02-27T13:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspargo-labs-strengthens-leadership-team-with-appointment-of-former-amgen-regulatory-expert-as-cro 2025-02-27T13:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/divesiran-shows-promise-in-phase-1-2-trial-for-polycythemia-vera-treatment 2025-02-27T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/divesiran-shows-promise-in-phase-1-2-trial-for-polycythemia-vera-treatment 2025-02-27T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/philippine-senator-urges-fast-track-approval-of-takeda-s-tak-003-dengue-vaccine-amid-56-case-surge 2025-02-27T13:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philippine-senator-urges-fast-track-approval-of-takeda-s-tak-003-dengue-vaccine-amid-56-case-surge 2025-02-27T13:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-bluerock-s-novel-cell-therapy-for-inherited-retinal-diseases 2025-02-27T13:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-bluerock-s-novel-cell-therapy-for-inherited-retinal-diseases 2025-02-27T13:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/higher-radon-exposure-linked-to-37-increased-risk-of-gestational-diabetes-in-first-time-pregnancies 2025-02-27T13:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/higher-radon-exposure-linked-to-37-increased-risk-of-gestational-diabetes-in-first-time-pregnancies 2025-02-27T13:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/eu-streamlines-clinical-trial-regulations-with-single-portal-system-to-accelerate-drug-development 2025-02-27T12:46:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-streamlines-clinical-trial-regulations-with-single-portal-system-to-accelerate-drug-development 2025-02-27T12:46:50+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-reports-strong-start-to-2025-with-strategic-partnerships-and-commercial-growth 2025-02-27T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-reports-strong-start-to-2025-with-strategic-partnerships-and-commercial-growth 2025-02-27T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vantage-secures-fda-drug-master-file-for-vycerintm-api-glycerin-enhancing-pharmaceutical-formulation-options 2025-02-27T11:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vantage-secures-fda-drug-master-file-for-vycerintm-api-glycerin-enhancing-pharmaceutical-formulation-options 2025-02-27T11:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-healthcare-cro-market-projected-to-reach-29-68-billion-by-2034-growing-at-7-1-cagr 2025-02-27T11:41:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-healthcare-cro-market-projected-to-reach-29-68-billion-by-2034-growing-at-7-1-cagr 2025-02-27T11:41:52+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-study-shows-60-of-critical-nicu-infants-should-receive-rapid-genome-sequencing 2025-02-27T11:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-study-shows-60-of-critical-nicu-infants-should-receive-rapid-genome-sequencing 2025-02-27T11:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/nanoform-reports-strong-growth-and-advances-in-nanoparticle-drug-development-pipeline 2025-02-27T10:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoform-reports-strong-growth-and-advances-in-nanoparticle-drug-development-pipeline 2025-02-27T10:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-for-gamifant-in-hlh-mas-associated-with-still-s-disease 2025-02-27T10:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-for-gamifant-in-hlh-mas-associated-with-still-s-disease 2025-02-27T10:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/dsmb-endorses-continuation-of-phase-3-dragon-trial-for-tinlarebant-in-stargardt-disease 2025-02-27T08:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dsmb-endorses-continuation-of-phase-3-dragon-trial-for-tinlarebant-in-stargardt-disease 2025-02-27T08:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/ai-investment-in-clinical-operations-set-to-surge-industry-leaders-project-2b-spending-by-2028 2025-02-27T08:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-investment-in-clinical-operations-set-to-surge-industry-leaders-project-2b-spending-by-2028 2025-02-27T08:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/iteos-secures-120m-funding-to-advance-tigit-antibody-program-in-nsclc 2025-02-27T08:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iteos-secures-120m-funding-to-advance-tigit-antibody-program-in-nsclc 2025-02-27T08:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/novel-approaches-transform-lymphoma-treatment-landscape-from-genomic-profiling-to-liquid-biopsies 2025-02-27T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-approaches-transform-lymphoma-treatment-landscape-from-genomic-profiling-to-liquid-biopsies 2025-02-27T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fluoguide-advances-phase-ii-head-and-neck-cancer-trial-following-successful-clinical-results 2025-02-27T07:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fluoguide-advances-phase-ii-head-and-neck-cancer-trial-following-successful-clinical-results 2025-02-27T07:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/lightlake-therapeutics-reports-phase-ii-success-for-novel-binge-eating-disorder-nasal-spray-treatment 2025-02-27T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lightlake-therapeutics-reports-phase-ii-success-for-novel-binge-eating-disorder-nasal-spray-treatment 2025-02-27T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncoinvent-completes-safety-lead-in-cohort-enrollment-for-novel-alpha-radiation-therapy-in-ovarian-cancer-trial 2025-02-27T07:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoinvent-completes-safety-lead-in-cohort-enrollment-for-novel-alpha-radiation-therapy-in-ovarian-cancer-trial 2025-02-27T07:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/surgery-shows-superior-outcomes-over-sabr-in-elderly-nsclc-patients-study-finds 2025-02-27T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgery-shows-superior-outcomes-over-sabr-in-elderly-nsclc-patients-study-finds 2025-02-27T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-miudella-first-new-copper-iud-in-four-decades-expands-contraceptive-options 2025-02-27T04:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-miudella-first-new-copper-iud-in-four-decades-expands-contraceptive-options 2025-02-27T04:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-micro-biosystems-and-merck-kgaa-sign-five-year-global-distribution-agreement-for-growth-direct-system 2025-02-27T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapid-micro-biosystems-and-merck-kgaa-sign-five-year-global-distribution-agreement-for-growth-direct-system 2025-02-27T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-launches-flyrcado-revolutionary-pet-imaging-agent-for-coronary-artery-disease 2025-02-27T01:32:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-launches-flyrcado-revolutionary-pet-imaging-agent-for-coronary-artery-disease 2025-02-27T01:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-launches-global-trial-for-prevail-drug-coated-balloon-in-coronary-artery-disease 2025-02-27T01:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-launches-global-trial-for-prevail-drug-coated-balloon-in-coronary-artery-disease 2025-02-27T01:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-itovebi-combination-for-advanced-breast-cancer-requires-careful-blood-sugar-monitoring 2025-02-27T01:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-itovebi-combination-for-advanced-breast-cancer-requires-careful-blood-sugar-monitoring 2025-02-27T01:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/uab-launches-comparative-study-of-dorzagliatin-vs-standard-therapies-for-type-2-diabetes-night-time-glucose-control 2025-02-27T01:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uab-launches-comparative-study-of-dorzagliatin-vs-standard-therapies-for-type-2-diabetes-night-time-glucose-control 2025-02-27T01:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-acquires-global-rights-to-zanidatamab-in-1-76-billion-deal-with-zymeworks 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-acquires-global-rights-to-zanidatamab-in-1-76-billion-deal-with-zymeworks 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-launches-comprehensive-sle-registry-to-address-critical-research-gaps 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-launches-comprehensive-sle-registry-to-address-critical-research-gaps 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-phathom-s-novel-h-pylori-treatments-securing-260m-financing-for-launch 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-phathom-s-novel-h-pylori-treatments-securing-260m-financing-for-launch 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-acquires-takeda-s-aurora-kinase-inhibitor-alisertib-for-7m-upfront 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puma-biotechnology-acquires-takeda-s-aurora-kinase-inhibitor-alisertib-for-7m-upfront 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approvals-of-lecanemab-and-donanemab-spark-divided-response-among-healthcare-professionals 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approvals-of-lecanemab-and-donanemab-spark-divided-response-among-healthcare-professionals 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/relay-therapeutics-to-launch-phase-3-trial-for-rly-2608-in-advanced-breast-cancer-mid-2025 2025-02-26T23:02:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relay-therapeutics-to-launch-phase-3-trial-for-rly-2608-in-advanced-breast-cancer-mid-2025 2025-02-26T23:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/pharnext-s-cmt1a-drug-pxt3003-fails-to-meet-primary-endpoint-in-phase-3-premier-trial 2025-02-26T23:01:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharnext-s-cmt1a-drug-pxt3003-fails-to-meet-primary-endpoint-in-phase-3-premier-trial 2025-02-26T23:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/kiniksa-reports-strong-arcalyst-growth-advances-kpl-387-for-recurrent-pericarditis-development 2025-02-26T22:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiniksa-reports-strong-arcalyst-growth-advances-kpl-387-for-recurrent-pericarditis-development 2025-02-26T22:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/loxo-435-shows-promise-as-selective-fgfr3-inhibitor-in-metastatic-urothelial-cancer-trial 2025-02-26T22:31:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/loxo-435-shows-promise-as-selective-fgfr3-inhibitor-in-metastatic-urothelial-cancer-trial 2025-02-26T22:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-of-antenatal-steroids-shows-progressive-benefits-for-extremely-preterm-infants 2025-02-26T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-of-antenatal-steroids-shows-progressive-benefits-for-extremely-preterm-infants 2025-02-26T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/experts-debate-value-of-ctdna-testing-in-muscle-invasive-bladder-cancer-management 2025-02-26T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-debate-value-of-ctdna-testing-in-muscle-invasive-bladder-cancer-management 2025-02-26T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/icad-and-koios-medical-unite-to-launch-comprehensive-ai-powered-breast-cancer-detection-platform 2025-02-26T20:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icad-and-koios-medical-unite-to-launch-comprehensive-ai-powered-breast-cancer-detection-platform 2025-02-26T20:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/ligand-pharmaceuticals-leads-75m-royalty-financing-for-d-fi-gene-therapy-in-rare-skin-disease-trial 2025-02-26T20:01:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ligand-pharmaceuticals-leads-75m-royalty-financing-for-d-fi-gene-therapy-in-rare-skin-disease-trial 2025-02-26T20:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/cargo-therapeutics-halts-cd22-cell-therapy-trial-sparks-debate-on-biotech-company-survival 2025-02-26T19:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cargo-therapeutics-halts-cd22-cell-therapy-trial-sparks-debate-on-biotech-company-survival 2025-02-26T19:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/novel-screening-technologies-enter-clinical-trial-to-detect-silent-esophageal-precancer 2025-02-26T19:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-screening-technologies-enter-clinical-trial-to-detect-silent-esophageal-precancer 2025-02-26T19:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funded-best-icu-trial-explores-behavioral-economics-to-enhance-critical-care-bundle-implementation 2025-02-26T19:31:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-funded-best-icu-trial-explores-behavioral-economics-to-enhance-critical-care-bundle-implementation 2025-02-26T19:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/immunocore-reports-strong-kimmtrak-sales-growth-and-advances-clinical-pipeline-in-2024 2025-02-26T17:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocore-reports-strong-kimmtrak-sales-growth-and-advances-clinical-pipeline-in-2024 2025-02-26T17:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/one-year-study-shows-sustained-benefits-of-arc-ex-therapy-in-spinal-cord-injury-patients 2025-02-26T17:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-year-study-shows-sustained-benefits-of-arc-ex-therapy-in-spinal-cord-injury-patients 2025-02-26T17:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-rejects-novartis-challenge-to-medicare-drug-price-negotiation-program 2025-02-26T17:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-rejects-novartis-challenge-to-medicare-drug-price-negotiation-program 2025-02-26T17:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/nielsen-biosciences-completes-phase-3-enrollment-for-novel-wart-treatment-candin 2025-02-26T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nielsen-biosciences-completes-phase-3-enrollment-for-novel-wart-treatment-candin 2025-02-26T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/eu-clinical-trials-regulation-takes-full-effect-as-life-sciences-sector-embraces-digital-transformation 2025-02-26T16:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-clinical-trials-regulation-takes-full-effect-as-life-sciences-sector-embraces-digital-transformation 2025-02-26T16:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/eikon-therapeutics-secures-351m-series-d-funding-to-advance-melanoma-treatment-to-phase-iii 2025-02-26T16:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eikon-therapeutics-secures-351m-series-d-funding-to-advance-melanoma-treatment-to-phase-iii 2025-02-26T16:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-and-gustave-roussy-launch-premis-study-to-predict-immunotherapy-side-effects 2025-02-26T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncohost-and-gustave-roussy-launch-premis-study-to-predict-immunotherapy-side-effects 2025-02-26T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/abcuro-secures-200m-series-c-to-advance-phase-ii-iii-trial-for-rare-muscle-disease-treatment 2025-02-26T16:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abcuro-secures-200m-series-c-to-advance-phase-ii-iii-trial-for-rare-muscle-disease-treatment 2025-02-26T16:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/zervimesine-shows-promise-in-geographic-atrophy-trial-building-on-success-in-multiple-cns-disorders 2025-02-26T16:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zervimesine-shows-promise-in-geographic-atrophy-trial-building-on-success-in-multiple-cns-disorders 2025-02-26T16:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-adcendo-s-novel-tissue-factor-targeting-adc-in-advanced-solid-tumors 2025-02-26T16:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-adcendo-s-novel-tissue-factor-targeting-adc-in-advanced-solid-tumors 2025-02-26T16:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/xanomeline-trospium-shows-promising-cognitive-benefits-in-schizophrenia-patients-with-baseline-impairment 2025-02-26T15:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xanomeline-trospium-shows-promising-cognitive-benefits-in-schizophrenia-patients-with-baseline-impairment 2025-02-26T15:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunoprecise-and-ribopro-form-strategic-alliance-to-advance-mrna-driven-antibody-discovery 2025-02-26T14:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoprecise-and-ribopro-form-strategic-alliance-to-advance-mrna-driven-antibody-discovery 2025-02-26T14:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-pyxis-oncology-s-pyx-201-for-advanced-head-and-neck-cancer 2025-02-26T14:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-pyxis-oncology-s-pyx-201-for-advanced-head-and-neck-cancer 2025-02-26T14:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/bipartisan-epic-act-seeks-to-eliminate-ira-s-small-molecule-drug-development-disincentive 2025-02-26T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bipartisan-epic-act-seeks-to-eliminate-ira-s-small-molecule-drug-development-disincentive 2025-02-26T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-s-dna-vaccine-shows-promising-immune-response-against-covid-19-in-phase-1-trial 2025-02-26T14:01:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imunon-s-dna-vaccine-shows-promising-immune-response-against-covid-19-in-phase-1-trial 2025-02-26T14:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/assembly-bio-initiates-phase-1a-trial-of-first-in-class-oral-hdv-entry-inhibitor-abi-6250 2025-02-26T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/assembly-bio-initiates-phase-1a-trial-of-first-in-class-oral-hdv-entry-inhibitor-abi-6250 2025-02-26T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wellgistics-partners-with-tollo-health-to-address-glp-1-side-effects-and-long-covid-through-medical-foods 2025-02-26T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wellgistics-partners-with-tollo-health-to-address-glp-1-side-effects-and-long-covid-through-medical-foods 2025-02-26T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-technologies-show-promise-in-amd-treatment-gene-therapy-and-light-based-interventions-take-center-stage 2025-02-26T13:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-technologies-show-promise-in-amd-treatment-gene-therapy-and-light-based-interventions-take-center-stage 2025-02-26T13:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/imetelstat-shows-promise-in-mds-and-myelofibrosis-treatment-new-ash-data-reveals 2025-02-26T13:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imetelstat-shows-promise-in-mds-and-myelofibrosis-treatment-new-ash-data-reveals 2025-02-26T13:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-opus-genetics-eye-drop-treatment-for-night-vision-impairment 2025-02-26T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-opus-genetics-eye-drop-treatment-for-night-vision-impairment 2025-02-26T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-orelabrutinib-shows-over-90-reduction-in-ms-brain-lesions-in-phase-ii-trial 2025-02-26T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-s-orelabrutinib-shows-over-90-reduction-in-ms-brain-lesions-in-phase-ii-trial 2025-02-26T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/kangpu-s-novel-molecular-glue-modulator-kpg-818-receives-ind-approval-in-china-for-multiple-myeloma-treatment 2025-02-26T13:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kangpu-s-novel-molecular-glue-modulator-kpg-818-receives-ind-approval-in-china-for-multiple-myeloma-treatment 2025-02-26T13:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-biopharma-advances-high-dose-sublingual-aspirin-development-following-successful-feasibility-study 2025-02-26T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspire-biopharma-advances-high-dose-sublingual-aspirin-development-following-successful-feasibility-study 2025-02-26T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/mtbvac-tb-vaccine-enters-landmark-phase-2b-trial-across-three-african-countries 2025-02-26T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mtbvac-tb-vaccine-enters-landmark-phase-2b-trial-across-three-african-countries 2025-02-26T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/geron-reports-strong-q4-2024-results-with-47-5-million-in-rytelo-revenue-expects-profitability-without-additional-financing 2025-02-26T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geron-reports-strong-q4-2024-results-with-47-5-million-in-rytelo-revenue-expects-profitability-without-additional-financing 2025-02-26T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-abanza-s-washercaptm-mini-for-meniscal-root-repair-and-acl-reconstruction 2025-02-26T12:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-abanza-s-washercaptm-mini-for-meniscal-root-repair-and-acl-reconstruction 2025-02-26T12:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/enodia-therapeutics-launches-with-novel-protein-degradation-platform-targeting-cancer-and-inflammatory-diseases 2025-02-26T12:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enodia-therapeutics-launches-with-novel-protein-degradation-platform-targeting-cancer-and-inflammatory-diseases 2025-02-26T12:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/leading-oncologists-share-critical-insights-on-managing-adc-therapies-in-clinical-practice 2025-02-26T12:12:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leading-oncologists-share-critical-insights-on-managing-adc-therapies-in-clinical-practice 2025-02-26T12:12:06+00:00 hourly 0.9 https://trial.medpath.com/news/experts-call-for-ecosystem-wide-approach-to-address-disparities-in-stem-cell-therapy-access 2025-02-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-call-for-ecosystem-wide-approach-to-address-disparities-in-stem-cell-therapy-access 2025-02-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-overhauls-healthcare-policy-major-cuts-to-medicaid-rfk-jr-confirmed-as-hhs-secretary 2025-02-26T10:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-overhauls-healthcare-policy-major-cuts-to-medicaid-rfk-jr-confirmed-as-hhs-secretary 2025-02-26T10:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-novel-breast-cancer-trial-combining-wee1-inhibitor-with-trodelvy 2025-02-26T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-novel-breast-cancer-trial-combining-wee1-inhibitor-with-trodelvy 2025-02-26T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/ignota-labs-secures-6-9m-to-revive-failed-drug-candidates-using-ai-platform 2025-02-26T08:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ignota-labs-secures-6-9m-to-revive-failed-drug-candidates-using-ai-platform 2025-02-26T08:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/kestra-medical-technologies-launches-ipo-aims-to-raise-140-160-million-for-cardiovascular-wearable-technology 2025-02-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kestra-medical-technologies-launches-ipo-aims-to-raise-140-160-million-for-cardiovascular-wearable-technology 2025-02-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/springworks-gomekli-approval-showcases-new-model-for-rescuing-shelved-rare-disease-drugs 2025-02-26T06:45:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/springworks-gomekli-approval-showcases-new-model-for-rescuing-shelved-rare-disease-drugs 2025-02-26T06:45:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approval-of-axatilimab-marks-new-era-in-chronic-gvhd-treatment 2025-02-26T06:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approval-of-axatilimab-marks-new-era-in-chronic-gvhd-treatment 2025-02-26T06:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/usaid-funding-freeze-threatens-global-clinical-trials-and-infectious-disease-research 2025-02-26T04:35:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usaid-funding-freeze-threatens-global-clinical-trials-and-infectious-disease-research 2025-02-26T04:35:55+00:00 hourly 0.9 https://trial.medpath.com/news/mobocertinib-fails-to-outperform-chemotherapy-in-first-line-egfr-exon-20-nsclc-trial 2025-02-26T04:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mobocertinib-fails-to-outperform-chemotherapy-in-first-line-egfr-exon-20-nsclc-trial 2025-02-26T04:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/triastek-s-3d-printed-drug-d23-shows-promising-targeted-delivery-for-iga-nephropathy-treatment 2025-02-26T04:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triastek-s-3d-printed-drug-d23-shows-promising-targeted-delivery-for-iga-nephropathy-treatment 2025-02-26T04:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/galcanezumab-shows-significant-promise-in-first-randomized-trial-for-vestibular-migraine-treatment 2025-02-26T04:31:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galcanezumab-shows-significant-promise-in-first-randomized-trial-for-vestibular-migraine-treatment 2025-02-26T04:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-organovo-s-fxr-agonist-program-for-ibd-in-60m-deal 2025-02-26T03:38:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-acquires-organovo-s-fxr-agonist-program-for-ibd-in-60m-deal 2025-02-26T03:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/terns-pharmaceuticals-advances-cml-drug-tern-701-and-obesity-treatment-tern-601-in-clinical-trials 2025-02-26T02:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terns-pharmaceuticals-advances-cml-drug-tern-701-and-obesity-treatment-tern-601-in-clinical-trials 2025-02-26T02:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-plans-three-major-phase-iii-trials-in-2025-for-attr-amyloidosis-and-hypertension 2025-02-26T01:31:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-plans-three-major-phase-iii-trials-in-2025-for-attr-amyloidosis-and-hypertension 2025-02-26T01:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-drug-for-feline-heart-disease-rapamycin-shows-promise-in-reversing-hcm 2025-02-26T01:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-drug-for-feline-heart-disease-rapamycin-shows-promise-in-reversing-hcm 2025-02-26T01:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/inovalon-launches-ai-powered-platform-to-transform-clinical-trial-patient-recruitment 2025-02-26T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovalon-launches-ai-powered-platform-to-transform-clinical-trial-patient-recruitment 2025-02-26T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/allogene-and-foresight-diagnostics-forge-37-3m-partnership-for-lymphoma-diagnostic-development 2025-02-26T00:01:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogene-and-foresight-diagnostics-forge-37-3m-partnership-for-lymphoma-diagnostic-development 2025-02-26T00:01:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-rare-disease-research-support-with-27-million-in-grants-and-new-innovation-hub 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-rare-disease-research-support-with-27-million-in-grants-and-new-innovation-hub 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/microbiotica-reveals-novel-mechanisms-of-microbiome-enhanced-immunotherapy-response-with-mb097 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiotica-reveals-novel-mechanisms-of-microbiome-enhanced-immunotherapy-response-with-mb097 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-in-class-tenapanor-for-hyperphosphatemia-in-dialysis-patients 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-in-class-tenapanor-for-hyperphosphatemia-in-dialysis-patients 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-secures-eu-ivdr-certification-for-food-intolerance-diagnostics-targeting-ibd-patients 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomerica-secures-eu-ivdr-certification-for-food-intolerance-diagnostics-targeting-ibd-patients 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-tidepool-loop-first-iphone-controlled-automated-insulin-dosing-app-for-type-1-diabetes 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-tidepool-loop-first-iphone-controlled-automated-insulin-dosing-app-for-type-1-diabetes 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gt-biopharma-secures-0-7m-through-strategic-warrant-exercise-for-trike-r-platform-development 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gt-biopharma-secures-0-7m-through-strategic-warrant-exercise-for-trike-r-platform-development 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/north-carolina-emerges-as-global-bioscience-hub-with-2-5b-international-investment-surge 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/north-carolina-emerges-as-global-bioscience-hub-with-2-5b-international-investment-surge 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/priavoid-completes-recruitment-for-phase-ii-alzheimer-s-drug-trial-of-pri-002 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priavoid-completes-recruitment-for-phase-ii-alzheimer-s-drug-trial-of-pri-002 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actio-biosciences-advances-precision-medicine-platform-for-rare-and-common-diseases 2025-02-25T23:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actio-biosciences-advances-precision-medicine-platform-for-rare-and-common-diseases 2025-02-25T23:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-success-ferumoxtran-shows-promise-in-detecting-small-prostate-cancer-metastases 2025-02-25T23:01:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-success-ferumoxtran-shows-promise-in-detecting-small-prostate-cancer-metastases 2025-02-25T23:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/ecopipam-shows-breakthrough-results-in-phase-3-trial-for-tourette-syndrome-treatment 2025-02-25T22:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ecopipam-shows-breakthrough-results-in-phase-3-trial-for-tourette-syndrome-treatment 2025-02-25T22:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-review-of-uzedy-for-bipolar-i-disorder-treatment-extension 2025-02-25T22:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-review-of-uzedy-for-bipolar-i-disorder-treatment-extension 2025-02-25T22:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/cooling-therapy-shows-no-benefit-for-preterm-infants-with-brain-injury-nih-study-finds 2025-02-25T22:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cooling-therapy-shows-no-benefit-for-preterm-infants-with-brain-injury-nih-study-finds 2025-02-25T22:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/elanco-s-credelio-quattro-breaks-new-ground-in-multi-parasite-protection-for-dogs 2025-02-25T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elanco-s-credelio-quattro-breaks-new-ground-in-multi-parasite-protection-for-dogs 2025-02-25T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-wearable-device-shows-97-accuracy-in-predicting-epileptic-seizures 2025-02-25T21:01:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-wearable-device-shows-97-accuracy-in-predicting-epileptic-seizures 2025-02-25T21:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/cema-cel-shows-promising-2-year-durability-data-in-large-b-cell-lymphoma-treatment 2025-02-25T20:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cema-cel-shows-promising-2-year-durability-data-in-large-b-cell-lymphoma-treatment 2025-02-25T20:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-shows-superior-efficacy-of-preservative-free-latanoprost-emulsion-for-glaucoma-treatment 2025-02-25T19:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-shows-superior-efficacy-of-preservative-free-latanoprost-emulsion-for-glaucoma-treatment 2025-02-25T19:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-bone-marrow-transplant-shows-88-cure-rate-for-sickle-cell-disease 2025-02-25T19:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-bone-marrow-transplant-shows-88-cure-rate-for-sickle-cell-disease 2025-02-25T19:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-facial-analysis-technology-enters-clinical-trials-for-depression-screening 2025-02-25T19:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-facial-analysis-technology-enters-clinical-trials-for-depression-screening 2025-02-25T19:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/england-leads-with-nhs-coverage-of-wegovy-and-mounjaro-for-obesity-while-australia-delays 2025-02-25T19:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/england-leads-with-nhs-coverage-of-wegovy-and-mounjaro-for-obesity-while-australia-delays 2025-02-25T19:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/agilus-diagnostics-partners-with-lucence-to-bring-advanced-cancer-liquid-biopsy-testing-to-india 2025-02-25T18:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agilus-diagnostics-partners-with-lucence-to-bring-advanced-cancer-liquid-biopsy-testing-to-india 2025-02-25T18:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/fulcrum-s-pociredir-scd-trial-advances-with-key-data-readouts-expected-in-2025 2025-02-25T18:03:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fulcrum-s-pociredir-scd-trial-advances-with-key-data-readouts-expected-in-2025 2025-02-25T18:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/novel-sonodynamic-therapy-demonstrates-promising-safety-and-efficacy-in-glioblastoma-treatment 2025-02-25T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-sonodynamic-therapy-demonstrates-promising-safety-and-efficacy-in-glioblastoma-treatment 2025-02-25T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-reports-strong-q4-2024-results-outlines-pipeline-milestones-for-2025 2025-02-25T17:02:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-biosciences-reports-strong-q4-2024-results-outlines-pipeline-milestones-for-2025 2025-02-25T17:02:18+00:00 hourly 0.9 https://trial.medpath.com/news/biological-e-s-14-valent-pneumococcal-vaccine-shows-promise-in-phase-3-trial 2025-02-25T16:34:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biological-e-s-14-valent-pneumococcal-vaccine-shows-promise-in-phase-3-trial 2025-02-25T16:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-status-to-radiprodil-for-grin-related-seizure-treatment 2025-02-25T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-status-to-radiprodil-for-grin-related-seizure-treatment 2025-02-25T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/nexobrid-shows-superior-results-in-phase-iii-pediatric-burn-treatment-study 2025-02-25T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexobrid-shows-superior-results-in-phase-iii-pediatric-burn-treatment-study 2025-02-25T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-assisted-therapy-shows-promise-in-small-fibromyalgia-trial 2025-02-25T16:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-assisted-therapy-shows-promise-in-small-fibromyalgia-trial 2025-02-25T16:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/healey-center-launches-als-mymatch-program-to-accelerate-early-phase-drug-development 2025-02-25T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healey-center-launches-als-mymatch-program-to-accelerate-early-phase-drug-development 2025-02-25T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/fembloc-non-surgical-birth-control-shows-100-effectiveness-in-clinical-trials-with-five-year-safety-data 2025-02-25T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fembloc-non-surgical-birth-control-shows-100-effectiveness-in-clinical-trials-with-five-year-safety-data 2025-02-25T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/cdr-life-and-boehringer-ingelheim-s-geographic-atrophy-treatment-advances-to-phase-2-clinical-trials 2025-02-25T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdr-life-and-boehringer-ingelheim-s-geographic-atrophy-treatment-advances-to-phase-2-clinical-trials 2025-02-25T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-s-lurie-cancer-center-joins-clinical-trial-testing-lixte-s-lb-100-plus-dostarlimab-for-ovarian-clear-cell-cancer 2025-02-25T16:32:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-s-lurie-cancer-center-joins-clinical-trial-testing-lixte-s-lb-100-plus-dostarlimab-for-ovarian-clear-cell-cancer 2025-02-25T16:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-s-rutherrin-shows-promise-in-non-hodgkin-s-lymphoma-treatment-when-combined-with-metformin-and-radiation 2025-02-25T16:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-s-rutherrin-shows-promise-in-non-hodgkin-s-lymphoma-treatment-when-combined-with-metformin-and-radiation 2025-02-25T16:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-secures-patent-for-novel-non-hallucinogenic-compounds-targeting-addiction-and-adhd 2025-02-25T16:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-secures-patent-for-novel-non-hallucinogenic-compounds-targeting-addiction-and-adhd 2025-02-25T16:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/vivici-secures-eur32-5m-series-a-to-launch-fermentation-derived-lactoferrin-in-2025 2025-02-25T15:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivici-secures-eur32-5m-series-a-to-launch-fermentation-derived-lactoferrin-in-2025 2025-02-25T15:31:00+00:00 hourly 0.9